Document:

Exhibit 10.9

    

    

      Cue Health Inc.

       

      2021 EMPLOYEE STOCK PURCHASE PLAN

       

      The purpose of this 2021 Employee Stock Purchase Plan (this “Plan”) is to provide eligible employees of Cue Health Inc. (the “Company”) and certain of its subsidiaries with
        opportunities to purchase shares of the Company’s common stock, $0.00001 par value per share (the “Common Stock”), commencing at such time and on such dates as the Board of Directors of the Company (the “Board”) shall determine.  Subject to
        adjustment under Section 15 hereof, the number of shares of Common Stock that have been approved for this purpose is the sum of:

       

      (a)          2,834,754 shares of Common Stock; plus

       

      (b)          an annual increase to be added on the first day of each fiscal
          year, commencing on January 1, 2022 and continuing for each fiscal year until, and including, January 1, 2032, equal to the least of (i) 8,504,263 shares of Common Stock, (ii) 1% of the outstanding shares on such date and (iii) a number of shares
          of Common Stock determined by the Board.

       

      This Plan is intended to qualify as an “employee stock purchase plan” as defined in Section 423 of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations issued
        thereunder, and shall be interpreted consistent therewith.

       

      1.          Administration.  The Plan will be administered by the Board or by a
          committee appointed by the Board (the “Committee”).  The Board or the Committee has authority to make rules and regulations for the administration of the Plan and its interpretation and decisions with regard thereto shall be final and conclusive.

       

      2.          Eligibility.  All employees of the Company and all employees of any
          subsidiary of the Company (as defined in Section 424(f) of the Code) designated by the Board or the Committee from time to time (a “Designated Subsidiary”), are eligible to participate in any one or more of the offerings of Options (as defined in
          Section 9) to purchase Common Stock under the Plan provided that:

       

      (a)          they are customarily employed by the Company or a Designated
          Subsidiary for more than 20 hours a week and for more than five months in a calendar year;

       

      (b)          they have been employed by the Company or a Designated
          Subsidiary for at least three months prior to enrolling in the Plan; and

       

      (c)          they are employees of the Company or a Designated Subsidiary on
          the first day of the applicable Plan Period (as defined below).

       

      No employee may be granted an Option hereunder if such employee, immediately after the Option is granted, owns 5% or more of the total combined voting power or value of the
        stock of the Company or any subsidiary.  For purposes of the preceding sentence, the attribution rules of Section 424(d) of the Code shall apply in determining the stock ownership of an employee, and all stock that the employee has a contractual
        right to purchase shall be treated as stock owned by the employee.

      
        
          

      

      
      The Company retains the discretion to determine which eligible employees may participate in an offering pursuant to and consistent with Treasury Regulation Sections
        1.423-2(e) and (f).

       

      3.          Offerings.  The Company will make one or more offerings (“Offerings”) to
          employees to purchase stock under this Plan.  Offerings will begin at such time and on such dates as the Board shall determine, or the first business day thereafter (such dates, the “Offering Commencement Dates”).  Each Offering Commencement Date
          will begin a six-month period (a “Plan Period”) during which payroll deductions will be made and held for the purchase of Common Stock at the end of the Plan Period.  However, the Board or the Committee may, at its discretion, choose a different
          Plan Period of not more than twelve (12) months for Offerings.

       

      4.          Participation.  An employee eligible on the Offering Commencement Date of
          any Offering may participate in such Offering by completing and forwarding either a written or electronic payroll deduction authorization form to the employee’s appropriate payroll office at least 15 days (or such other number of days as is
          determined by the Company) prior to the applicable Offering Commencement Date.  The form will authorize a regular payroll deduction from the Compensation received by the employee during the Plan Period.  Unless an employee files a new form or
          withdraws from the Plan, his or her deductions and purchases will continue at the same rate for future Offerings under the Plan as long as the Plan remains in effect.  The term “Compensation” means the amount of money reportable on the employee’s
          Federal Income Tax Withholding Statement (or analogous non-U.S. statement), excluding overtime, shift premium, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances for travel expenses, income or
          gains associated with the grant or vesting of restricted stock, income or gains on the exercise of Company stock options or stock appreciation rights, and similar items, whether or not shown or separately identified on the employee’s Federal
          Income Tax Withholding Statement (or analogous non-U.S. statement), but including, in the case of salespersons, sales commissions to the extent determined by the Board or the Committee.

       

      5.          Deductions.  The Company will maintain payroll deduction accounts for all
          participating employees.  With respect to any Offering made under this Plan, an employee may authorize a payroll deduction in any percentage amount (in whole percentages) up to a maximum of 15% of the Compensation he or she receives during the
          Plan Period or such shorter period during which deductions from payroll are made.  The Board or the Committee may, at its discretion, designate a lower maximum contribution rate. The minimum payroll deduction is such percentage of Compensation as
          may be established from time to time by the Board or the Committee.

       

      6.          Deduction Changes.  An employee may decrease or discontinue his or her
          payroll deduction once during any Plan Period, by filing either a written or electronic new payroll deduction authorization form, as determined by the Company.  However, an employee may not increase his or her payroll deduction during a Plan
          Period.  If an employee elects to discontinue his or her payroll deductions during a Plan Period, but does not elect to withdraw his or her funds pursuant to Section 8 hereof, funds deducted prior to his or her election to discontinue will be
          applied to the purchase of Common Stock on the Exercise Date (as defined below).

      
        -2-

        
          

      

      7.          Interest.  Interest will not be paid on any employee accounts, except to the
          extent that the Board or the Committee, in its sole discretion, elects to credit employee accounts with interest at such rate as it may from time to time determine.

       

      8.          Withdrawal of Funds.  An employee may at any time prior to the close of
          business on the fifteenth business day prior to the end of a Plan Period (or such other number of days as is determined by the Company) and for any reason permanently draw out the balance accumulated in the employee’s account and thereby withdraw
          from participation in an Offering.  Partial withdrawals are not permitted.  The employee may not begin participation again during the remainder of the Plan Period during which the employee withdrew his or her balance.  The employee may
          participate in any subsequent Offering in accordance with terms and conditions established by the Board or the Committee.

       

      9.          Purchase of Shares.

       

      (a)          Number of Shares.          On the Offering Commencement Date for the
          applicable Plan Period, the Company will grant to each eligible employee who is then a participant in the Plan an option (an “Option”) to purchase on the last business day of such Plan Period (the “Exercise Date”) at the applicable purchase price
          (the “Option Price”) up to that whole number of shares of Common Stock determined by multiplying $2,083 by the number of full months in the Plan Period and dividing the result by the closing price (as determined below) on the Offering
          Commencement Date; provided, however, that no employee may be granted an Option which permits his or her rights to purchase Common Stock under this Plan and any other employee stock purchase plan (as defined in Section 423(b) of the Code) of the
          Company and its subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such Common Stock (determined at the date such Option is granted) for each calendar year in which the Option is outstanding at any time; and,
          provided, further, however, that the Committee may, in its discretion, set a fixed maximum number of shares of Common Stock that each eligible employee may purchase per Plan Period which number may not be greater than the number of shares of
          Common Stock determined by using the formula in the first clause of this Section 9(a) and which number shall be subject to the second clause of this Section 9(a).

       

      (b)          Option Price.          The Board or the Committee shall determine the
          Option Price for each Plan Period, including whether such Option Price shall be determined based on the lesser of the closing price of the Common Stock on (i) the first business day of the Plan Period or (ii) the Exercise Date, or shall be based
          solely on the closing price of the Common Stock on the Exercise Date; provided, however, that such Option Price shall be at least 85% of the applicable closing price.  In the absence of a determination by the Board or the Committee, the Option
          Price will be 85% of the lesser of the closing price of the Common Stock on (i) the first business day of the Plan Period or (ii) the Exercise Date.  The closing price shall be (a) the closing price (for the primary trading session) on any
          national securities exchange on which the Common Stock is listed or (b) the average of the closing bid and asked prices in the over-the-counter-market, whichever is applicable, as published in The Wall Street Journal or another source
          selected by the Board or the Committee.  If no sales of Common Stock were made on such a day, the price of the Common Stock shall be the reported price for the next preceding day on which sales were made.

      
        -3-

        
          

      

      (c)          Exercise of Option.          Each employee who continues to be a
          participant in the Plan on the Exercise Date shall be deemed to have exercised his or her Option at the Option Price on such date and shall be deemed to have purchased from the Company the number of whole shares of Common Stock reserved for the
          purpose of the Plan that his or her accumulated payroll deductions on such date will pay for, but not in excess of the maximum numbers determined in the manner set forth above.

       

      (d)          Return of Unused Payroll Deductions.  Any balance remaining in an
          employee’s payroll deduction account at the end of a Plan Period will be automatically refunded to the employee, except that any balance that is less than the purchase price of one share of Common Stock will be carried forward into the employee’s
          payroll deduction account for the following Offering, unless the employee elects not to participate in the following Offering under the Plan, in which case the balance in the employee’s account shall be refunded.

       

      10.          Issuance of Certificates.  Certificates representing shares of Common Stock
          purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or (in the Company’s sole discretion) in the name of a brokerage
          firm, bank, or other nominee holder designated by the employee.  The Company may, in its sole discretion and in compliance with applicable laws, authorize the use of book entry registration of shares in lieu of issuing stock certificates.

       

      11.          Rights on Retirement, Death or Termination of Employment.  If a
          participating employee’s employment ends before the last business day of a Plan Period, no payroll deduction shall be taken from any pay then due and owing to the employee and the balance in the employee’s account shall be paid to the employee. 
          In the event of the employee’s death before the last business day of a Plan Period, the Company shall, upon notification of such death, pay the balance of the employee’s account (a) to the executor or administrator of the employee’s estate or
          (b) if no such executor or administrator has been appointed to the knowledge of the Company, to such other person(s) as the Company may, in its discretion, designate.  If, before the last business day of the Plan Period, the Designated Subsidiary
          by which an employee is employed ceases to be a subsidiary of the Company, or if the employee is transferred to a subsidiary of the Company that is not a Designated Subsidiary, the employee shall be deemed to have terminated employment for
          the purposes of this Plan.

       

      12.          Optionees Not Stockholders.  Neither the granting of an Option to an
          employee nor the deductions from his or her pay shall make such employee a stockholder of the shares of Common Stock covered by an Option under this Plan until he or she has purchased and received such shares.

       

      13.          Options Not Transferable.  Options under this Plan are not transferable by
          a participating employee other than by will or the laws of descent and distribution, and are exercisable during the employee’s lifetime only by the employee.

      
        -4-

        
          

      

      14.          Application of Funds.  All funds received or held by the Company under this
          Plan may be combined with other corporate funds and may be used for any corporate purpose.

       

      15.          Adjustment for Changes in Common Stock and Certain Other Events.

       

      (a)          Changes in Capitalization.  In the event of any stock split, reverse stock
          split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash
          dividend, (i) the number and class of securities available under this Plan, (ii) the share limitations set forth in Section 9, and (iii) the Option Price shall be equitably adjusted to the extent determined by the Board or the Committee.

       

      (b)          Reorganization Events.

       

      (1)          Definition.  A “Reorganization Event” shall mean:  (a) any merger or
          consolidation of the Company with or into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any transfer or
          disposition of all of the Common Stock of the Company for cash, securities or other property pursuant to a share exchange or other transaction or (c) any liquidation or dissolution of the Company.

      

      

      (2)          Consequences of a Reorganization Event on Options.  In connection with a
          Reorganization Event, the Board or the Committee may take any one or more of the following actions as to outstanding Options on such terms as the Board or the Committee determines:  (i) provide that Options shall be assumed, or substantially
          equivalent Options shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to employees, provide that all outstanding Options will be terminated immediately prior to the consummation of
          such Reorganization Event and that all such outstanding Options will become exercisable to the extent of accumulated payroll deductions as of a date specified by the Board or the Committee in such notice, which date shall not be less than ten
          (10) days preceding the effective date of the Reorganization Event, (iii) upon written notice to employees, provide that all outstanding Options will be cancelled as of a date prior to the effective date of the Reorganization Event and that all
          accumulated payroll deductions will be returned to participating employees on such date, (iv) in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each
          share surrendered in the Reorganization Event (the “Acquisition Price”), change the last day of the Plan Period to be the date of the consummation of the Reorganization Event and make or provide for a cash payment to each employee equal to
          (A) (1) the Acquisition Price times (2) the number of shares of Common Stock that the employee’s accumulated payroll deductions as of immediately prior to the Reorganization Event could purchase at the Option Price, where the Acquisition Price is
          treated as the fair market value of the Common Stock on the last day of the applicable Plan Period for purposes of determining the Option Price under Section 9(b) hereof, and where the number of shares that could be purchased is subject to the
          limitations set forth in Section 9(a), minus (B) the result of multiplying such number of shares by such Option Price, (v) provide that, in connection with a liquidation or dissolution of the Company, Options shall convert into the right to
          receive liquidation proceeds (net of the Option Price thereof) and (vi) any combination of the foregoing.

      
        -5-

        
          

      

      For purposes of clause (i) above, an Option shall be considered assumed if, following consummation of the Reorganization Event, the Option confers the right to purchase, for
        each share of Common Stock subject to the Option immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common
        Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding
        shares of Common Stock); provided, however, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the
        consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise of Options to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate
        thereof) that the Board determines to be equivalent in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the
        Reorganization Event.

       

      16.          Amendment of the Plan.  The Board may at any time, and from time to time,
          amend or suspend this Plan or any portion thereof, except that (a) if the approval of any such amendment by the shareholders of the Company is required by Section 423 of the Code, such amendment shall not be effected without such approval, and
          (b) in no event may any amendment be made that would cause the Plan to fail to comply with Section 423 of the Code.

       

      17.          Insufficient Shares.  If the total number of shares of Common Stock
          specified in elections to be purchased under any Offering plus the number of shares purchased under previous Offerings under this Plan exceeds the maximum number of shares issuable under this Plan, the Board or the Committee will allot the shares
          then available on a pro-rata basis.

       

      18.          Termination of the Plan.  This Plan may be terminated at any time by the
          Board.  Upon termination of this Plan all amounts in the accounts of participating employees shall be promptly refunded.

       

      19.          Governmental Regulations.  The Company’s obligation to sell and deliver
          Common Stock under this Plan is subject to listing on a national stock exchange (to the extent the Common Stock is then so listed or quoted) and the approval of all governmental authorities required in connection with the authorization, issuance
          or sale of such stock.

       

      20.          Governing Law.  The Plan shall be governed by Delaware law except to the
          extent that such law is preempted by federal law.

       

      21.          Issuance of Shares.  Shares may be issued upon exercise of an Option from
          authorized but unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source.

       

      22.          Notification upon Sale of Shares.  Each employee agrees, by participating
          in the Plan, to promptly give the Company notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased.

      
        -6-

        
          

      

      23.          Grants to Employees in Foreign Jurisdictions.  The Company may, to comply
          with the laws of a foreign jurisdiction, grant Options to employees of the Company or a Designated Subsidiary who are citizens or residents of such foreign jurisdiction (without regard to whether they are also citizens of the United States or
          resident aliens (within the meaning of Section 7701(b)(1)(A) of the Code)) with terms that are less favorable (but not more favorable) than the terms of Options granted under the Plan to employees of the Company or a Designated Subsidiary who are
          resident in the United States.  Notwithstanding the preceding provisions of this Plan, employees of the Company or a Designated Subsidiary who are citizens or residents of a foreign jurisdiction (without regard to whether they are also citizens
          of the United States or resident aliens (within the meaning of Section 7701(b)(1)(A) of the Code)) may be excluded from eligibility under the Plan if (a) the grant of an Option under the Plan to a citizen or resident of the foreign jurisdiction
          is prohibited under the laws of such jurisdiction or (b) compliance with the laws of the foreign jurisdiction would cause the Plan to violate the requirements of Section 423 of the Code.  The Company may add one or more appendices to this Plan
          describing the operation of the Plan in those foreign jurisdictions in which employees are excluded from participation or granted less favorable Options.

       

      24.          Authorization of Sub-Plans.  The Board may from time to time establish one
          or more sub-plans under the Plan with respect to one or more Designated Subsidiaries, provided that such sub-plan complies with Section 423 of the Code.

       

      25.          Withholding.  If applicable tax laws impose a tax withholding obligation,
          each affected employee shall, no later than the date of the event creating the tax liability, make provision satisfactory to the Board for payment of any taxes required by law to be withheld in connection with any transaction related to Options
          granted to or shares acquired by such employee pursuant to the Plan.  The Company may, to the extent permitted by law, deduct any such taxes from any payment of any kind otherwise due to an employee.

       

      26.          Effective Date and Approval of Shareholders.  The Plan shall take effect as
          of immediately prior to the effectiveness of the Company’s registration statement with respect to its initial public offering, subject to approval by the shareholders of the Company as required by Section 423 of the Code, which approval must
          occur within twelve months of the adoption of the Plan by the Board.

       

      
        	
                 

              	Adopted by the Board of Directors on
	
                 

              	[______], 2021
	
                 

              	
                 

              
	
                 

              	Approved by the stockholders on

                
	
                 

              	[______], 2021

      

    

     

    

  

  -7-Exhibit 10.11 

   

   

   

  
     

    
      
 

  

   

  Section B - Supplies or Services and Prices

   

  	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	0001	 	1	Lot	$184,576,636.62	$184,576,636.62
	 	
          Industrial Expansion (FFP)FFP

          INDUSTRIAL EXPANSION IN ACCORDANCE WITH AWARD

              SPECIFICATIONS

          FOB: Origin (Shipping Point)

          PURCHASE REQUEST NUMBER: 0011560601

          PSC CD: AN14

        	 
	 	 	 
	 	NET AMT	$184,576,636.62
	 	ACRN AA	 
	 	CIN: GFEBS001156060100001	$184,576,636.62

   

  	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	0002	 	6,000,000	Each	$[**]	$[**]
	 	
          Test Cartridges (FFP)FFP

          COVID-19 TEST CARTRIDGES AS SPECIFIED IN AWARD NARRATIVE

          FOB: Orgin (Shipping Point)

          PURCHASE REQUEST NUMBER: 0011560601

          PSC CD: AN14

        	 
	 	 	 
	 	NET AMT	$[**]
	 	ACRN AA	 
	 	CIN: GFEBS001156060100002	$[**]

   

  
     

    
      
 

  

   

  	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	0003	 	30,000	Each	$[**]	$[**]
	 	
          Monitoring Systems (FFP)FFP

          MONITORING SYSTEMS AS SPECIFIED IN AWARD NARRATIVE

          FOB: Origin (Shipping Point)

          PURCHASE REQUEST NUMBER: 0011560601

          PSC CD: AN14

        	 
	 	 	 
	 	NET AMT	$[**]
	 	ACRN AA	 
	 	CIN: GFEBS001156060100003	$[**]
	 	 	 

  	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	0004	 	60,000	Each	$[**]	$[**]
	 	
          Swab Packs (FFP)FFP

          SWAB PACKS AS SPECIFIED IN AWARD NARRATIVE

          FOB: Origin (Shipping Point)

          PURCHASE REQUEST NUMBER: 0011560601

          PSC CD: AN14

        	 
	 	 	 
	 	NET AMT	$[**]
	 	ACRN AA	 
	 	CIN: GFEBS001156060100004	$[**]

   

  
     

    
      
 

  

   

  Section C - Descriptions and Specifications

   

  OTHER TRANSACTION AGREEMENT

   

  OTHER TRANSACTION AUTHORITY FOR PROTOTYPE

      AGREEMENT

      BETWEEN

   

  Cue Health, Inc. (Awardee)

      And

      Army Contracting Command - Aberdeen Proving Ground - Research Triangle Park, NC DIVISION

      (Government)

      800 Park Office Drive Research Triangle Park, NC 27529

   

  Effective Date: October 13, 2020

   

  Agreement No.: W911NF-21-9-0001

   

  Total Amount of the Agreement: $480,916,636

   

  	Awardee

            Signature	 	Government

            Signature
	
           

          Ayub Khattak

        	 	
	
          Printed Name

           

          CEO

        	 	
          Printed Name

           

          Agreements Officer

        

   

  
     

    
      
 

  

   

  TABLE OF CONTENTS

   

  ARTICLE 1: BACKGROUND, DEFINITIONS AND SCOPE OF THE AGREEMENT

  ARTICLE 2: TERM AND TERMINATION

  ARTICLE 3: PROJECT MANAGEMENT AND MODIFICATIONS

  ARTICLE 4: MANAGEMENT OF THE PROJECT

  ARTICLE 5: “PREP ACT” COVERAGE

  ARTICLE 6: FINANCIAL MATTERS

  ARTICLE 7: DISPUTES

  ARTICLE 8: CONFIDENTIAL INFORMATION

  ARTICLE 9: INTELLECTUAL PROPERTY RIGHTS

  ARTICLE 10: DATA RIGHTS

  ARTICLE 11: REGULATORY RIGHTS

  ARTICLE 12: FOREIGN ACCESS TO DATA

  ARTICLE 13: SCIENTIFIC PUBLICATIONS AND PRESS RELEASES

  ARTICLE 14: ENSURING SUFFICIENT SUPPLY OF THE PRODUCT

  ARTICLE 15: INSPECTION AND ACCEPTANCE

  ARTICLE 16: REPORTING REQUIREMENTS

  ARTICLE 17: MISCELLANEOUS CLAUSES

  ARTICLE 18: PROHIBITION ON THE USE OF CERTAIN TELECOMMUNICATIONS AND VIDEO SURVEILLANCE SERVICES OR EQUIPMENT

  APPENDIX A: STATEMENT OF WORK

  APPENDIX B: PROJECT SCHEDULE/MILESTONE PAYMENT SCHEDULE

  APPENDIX C: KEY PERSONNEL

  APPENDIX D: GOVERNMENT PROPERTY

   

  
     

    
      
 

  

   

  OTHER TRANSACTION AUTHORITY FOR PROTOTYPE

      AGREEMENT

   

  This Other Transaction Authority for Prototype Agreement is entered into between the United States of
      America, hereinafter called the “Government”, pursuant to and under U.S. Federal law and Cue Health Inc., a small business and non-traditional defense contractor, hereinafter called the “Awardee”. The United States of America and Awardee are
      sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

   

  WHEREAS, the Awardee is eligible for an Other Transaction Authority for Prototype Agreement in
      accordance with 10 USC § 2371b(d)(1)(A) as amended by the National Defense Authorization Act for Fiscal Year 2018 as they are non-traditional defense contractor, attesting to “An entity that is not currently performing and has not performed, for at
      least the one-year period preceding the solicitation of sources by the Department of Defense for the procurement or transaction, any contract or subcontract for the Department of Defense that is subject to the full coverage under the cost accounting
      standards prescribed pursuant to Section 1502 of title 41 and the regulations implementing such section”;

   

  WHEREAS, the DoD currently has authority under 10 U.S.C. § 2371b to award “other transactions” (OTs) in
      certain circumstances for prototype projects that are directly relevant to enhancing the mission effectiveness of military personnel and the supporting platforms, systems, components, or materials proposed to be acquired or developed by the DoD, or
      to improve platforms, systems, components, or materials in use by the Armed Forces;

   

  WHEREAS, a prototype can generally be described as a physical or virtual model used to evaluate the
      technical or manufacturing feasibility or military utility of a particular technology or process, concept, end item, or system;

   

  WHEREAS, this Agreement meets the criteria for a prototype project;

   

  NOW THEREFORE, the Parties have agreed as follows:

   

  ARTICLE 1:   BACKGROUND, DEFINITIONS AND SCOPE OF THE AGREEMENT

   

  		A.	Background

   

  The Department of Health and Human Services through DoD requires the ability to procure reliable point of care
      testing assays and devices in sufficient quantities to meet the demand to respond to the on-going COVID-19 Pandemic. The unprecedented demand for rapid and accurate molecular diagnostic testing continues to exceed national testing capacity. Awardee,
      through funding provided by HHS, has already developed and received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a rapid, portable, point of care COVID-19 test capable of detecting SARS-CoV-2, the virus that
      causes COVID-19. The ability to deploy substantial quantities of the Cue POC COVID-19 test will not only increase national test capacity, but significantly reduce the time to inform patients of their result. The Cue Health test is anticipated to be
      used primarily in particular settings of concern, such as nursing homes, long term care facilities and schools. It will also be beneficial to the armed services and the US population at large, at other locations where a laboratory capability is not
      readily accessible. The Cue COVID-19 Test consists of: 1.) the Cue COVID-19 Test Cartridge pack which includes a single use test cartridge and a single use Sample Wand (swab); 2.) The Cue Health Monitoring System (reader); The Cue COVID-19 External
      Control Swabs Pack. Hereafter, the components of the test as necessary for a single use are collectively referred to as a “COVID-19 Test”.

   

  
     

    
      
 

  

   

  		B.	Definitions

   

  Agreement Invention: Any invention conceived or first actually reduced to practice in the performance of
      the Prototype Project under this Agreement.

   

  Agreements Officer or AO: Warranted contracting officer authorized to sign the final OTA for the
      Government.

   

  Agreement’s Officer’s Representative or AOR: The individual designated by the Government to monitor all
      technical aspects and assist in agreement administration of the Prototype Project. The AOR shall only assist in agreement administration of the Prototype Project to the extent delegated such administration authority in writing in the AOR delegation
      letter by the responsible Agreements Officer.

   

  Background Invention: Background Invention means any Invention, or improvement to any Invention, other
      than an Agreement Invention, that was conceived, designed, developed, produced, and/or reduced to practice prior to performance of this Agreement, or outside the scope of work performed under this Agreement.

   

  Cause: An event or issue that has been discovered that the Government believes may impact successful
      performance of the OTA.

   

  Date of Completion: The date on which all work is completed or the date on which the period of
      performance ends.

   

  		●	Deliverable(s): Any documentation (e.g. report, Executive Summary, Letter) given to the Government by the Awardee
            as described in the second column of Table 1 in Article I, Section C.7 under the heading “Deliverable.”

   

  		●	Effective Date: The date of execution of this Agreement by the Parties.

   

  		●	Field: COVID-19 Diagnostic testing.

   

  		●	Government: The United States of America, as represented by The Department of Defense and the Department of
            Health and Human Services.

   

  		●	Government Purpose Rights: As defined in DFARS 252.227-7013(a)(13).

   

  
     

    
      
 

  

   

  		●	Invention: Any invention or discovery which is or may be patentable or otherwise protectable under Title 35 of
            the United States Code.

   

  		●	Know-How: Information, practical knowledge, techniques, and skill development by Awardee in the performance of
            the Prototype Project and which is necessary for the Practical Application of an Agreement Invention within the Field.

   

  		●	Limited Rights: As defined in DFARS 252.227-7013(a)(14).

   

  		●	Party: Each of the Government and Awardee. (collectively, “Parties”).

   

  		●	Practical Application: With respect to an Agreement Invention, to manufacture, in the case of a composition of
            product; to practice, in the case of a process or method, or to operate, in the case of a machine or system; and, in each case, under such conditions so as to establish that the Agreement Invention is capable of being utilized.

   

  		●	Program: Prototype efforts being conducted by the Parties pursuant to this Agreement.

   

  		●	Prototype Project: Has the meaning given in Article 1.C.

   

  		●	Project Coordination Team or PCT: Agreements Officer, Agreements Officer’s Representative, Subject Matter Experts
            and Team Leader(s) acting in support of Operation Warp Speed and responsible for periodic and ad-hoc reporting to Operation Warp Speed Leadership.

   

  		●	Property: Any tangible personal property other than property actually consumed during the execution of work under
            this Agreement.

   

  		●	Under this Agreement: When used, for example but without limitation, in the definitions of Data, Know-How,
            Property, and Agreement Inventions, means activities conducted pursuant to this Agreement that are Government funded.

   

  Scope of the Agreement

   

  		1.	Prototype Project: The prototype project under this Agreement is the demonstration by Awardee of the rapid, large
            scale supply and logistics capability to manufacture and deliver to the Government within 5 months of the effective date of this Agreement 6 million Cue COVID-19 Assay Cartridges, 60,000 COVID-19 Control Swab Packs, and 30,000 Monitoring
            Systems by achieving a sustained average per day production rate of at least 100,000 EUA or 510(k) cleared Cue COVID-19 Assay Cartridges over the last 7 days of the 5 month delivery period. The expansion of Awardee’s manufacturing capability
            will likely entail several actions. The company will increase their overall output of assay cartridges by installing additional high capacity automated lines. Additionally the Awardee will upgrade their bio production capability to ensure
            enough reagent materials are available to meet end-state test cartridge manufacturing goals. In addition Awardee will perform activities required to onshore Monitoring System manufacturing to be performed either in-house, with a US-based
            contract manufacturing organization or both. The demonstrated manufacturing capability will be in compliance with ISO 13485 standards as well as the Quality System Regulations at 21 CFR Part 820.

   

  
     

    
      
 

  

   

  In order to ensure the successful and expeditious completion of this prototype project, Awardee agrees
      and represents that, commencing on the effective date of this Agreement, the Government will be the exclusive purchaser of the entire production of Awardee’s COVID-19 Test until the prototype project has been successfully completed. This exclusive
      purchaser condition is waived under the following circumstances: 1) Awardee may honor contractual commitments executed before the effective date of this Agreement and 2) Awardee may request a waiver from the Government to respond to other than U.S.
      Federal Government urgent diagnostic testing requirements and 3) Awardee may use a reasonable number of tests for internal workforce testing and diagnostic purposes and for marketing, demonstration and evaluation and business development. The
      prototype project will be successfully completed when Awardee has achieved a sustained average per day production rate of at least 100,000 EUA or 510(k) cleared COVID-19 Assay Cartridges over a 7 day period, and has delivered a total of 6 million Cue
      COVID-19 Assay Cartridges, 30,000 monitoring systems, and 60,000 control swab packs.

   

  		2.	Associated Production: It is the intention of the Parties to enter into a separate, but associated, sole-source
            FAR-based contract for the continued production of COVID-19 Tests. Subject to applicable law and regulation, the Parties shall take all steps necessary to negotiate and enter into such a FAR-based contract in good faith with the intent of
            promptly signing such FAR-based contract as soon as possible after this Agreement. Follow- on production pursuant to 10 USC 2371b is not anticipated for this project. In recognition of, and in consideration for, the Government’s significant
            funding for the development of Awardee’s enhanced manufacturing capability, the U.S. Government shall be entitled to purchase Awardee’s EUA or 510(k) cleared COVID-19 Test under a future FAR-based contract, in quantities not to exceed [**]
            percent ([**]%), measured on a quarterly basis, of Awardee’s COVID-19 Tests produced from the capacity as provided hereunder, at pricing that shall not exceed [**] percent ([**]%) below the lowest price then offered by Awardee to a commercial
            customer as of the date of the relevant order, for the same products, for equivalent quantities and under comparable delivery schedules and other terms of sale, provided, however, that Awardee shall have no obligation to accept any such
            discounted price less than $[**] per COVID-19 Test. Additionally, Awardee shall grant the Government the right to place such orders as Priority Orders (as defined below) for which Government purchase orders will be prioritized by Awardee as if
            they were “rated orders” subject to 15 CFR § 700.14, subject to the priority afforded to orders that are expressly identified as HRPAS or DPAS rated orders.

   

  		3.	Manufacturing Equipment Purchased With Government Funds: In recognition of, and in consideration for, the
            Government’s significant funding for the development of Awardee’s enhanced manufacturing capability, the Awardee agrees to never re-locate outside of the United States or its Territories any of the Automated Assembly Line equipment purchased
            with Government funds under this Agreement.

   

  		4.	Performance by Affiliates: The Government acknowledges and agrees that Awardee may perform its obligations under
            this Agreement through one or more of its affiliates and/or subcontractors, provided that Awardee will be responsible for the full and timely performance as and when due under, and observance of, all the covenants, terms, conditions and
            agreements set forth in this Agreement by its affiliates and/or subcontractors.

   

  
     

    
      
 

  

   

  		5.	Audits: Until such time as all tests, Monitoring Systems and control packs have been delivered under this
            Agreement, and in no event after expiration of the Period of Performance, audits under this Prototype Agreement may include Government Quality Assurance audits - periodic, ad hoc or for cause - of Awardee’s or sub-agreement holders’
            facilities included in the supply chain. The Government will provide notification of a periodic or ad hoc audit at least [**] prior to the intended audit date and both parties will work in good faith to accommodate the audit and
            determine scheduling. In all audits, the Government will comply with the Person in Plant requirements set forth in Article 1.C.7.

   

  		6.	Person in Plant: The Government may request to have a government representative in place at Awardee’s facility,
            with no fewer than [**] advance notice of the desired date for that person to be in place. The name, role, scope and duration will be mutually agreed between the Parties in writing in advance. The Government representative will adhere to the
            agreed scope and to the Awardee’s policies, procedures and instructions at all times. As determined by federal law, no Government representative shall publish, divulge, disclose, or make known in any manner, or to any extent not authorized by
            law, any information coming to him in the course of employment or official duties, while stationed in a Awardee plant.

   

  If considered for cause, the Government may place representatives in place at Awardee’s facility, with
      no fewer than [**] advance notice of the desired date for the person(s) to be in place, subject to applicable COVID protocols. The names, roles, scope, and duration will be provided to the Awardee in advance. The Government representative will adhere
      to the Awardee’s policies, procedures and instructions regarding facility regulations at all times. As determined by federal law, no Government representative shall publish, divulge, disclose, or make known in any manner, or to any extent not
      authorized by law, any information coming to him in the course of employment or official duties, while stationed in a Awardee plant.

   

  		7.	Deliverables: Deliverables under this Agreement are listed in Table 1.

            Variances: Awardee shall promptly notify the Government of any anticipated shortage in quantity or deviation from any delivery date specified herein. The Government and the Awardee shall cooperate in good faith to adjust Table 1 to
            reflect reasonable variations in the delivery schedule, provided that the total scheduled quantities are delivered and Awardee demonstrates a production capacity of 100,000 units per day within not more than [**] after award.

   

  
     

    
      
 

  

   

  Table 1: Deliverables

   

  	Item	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]
	COVID-19 Test Cartridges	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]
	Health Monitoring Systems	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]
	COVID-19 External Control Swab Packs	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]

   

  * Delivery dates and quantities subject to adjustment as provided herein.

   

  	Deliverable	Delivery

              Date	Method for Acceptance
	Increase

              Industrial Base Manufacturing Capability to 100K Cue COVID-19 Test cartridges per day	
          6 Million EUA or 510(k) cleared COVID-19 Test Cartridges 

          (per delivery schedule above) 

          30K Health Monitoring Systems

          (per delivery schedule above) 

          60K COVID-19 External Control Swab Packs 

          (per delivery schedule above)

        	Periodic Inspection & Random Sampling (DCMA and AOR)
	Monthly

              Progress Reports	[**] of the month, every month during PoP	Progress Report (AOR)
	Weekly Progress
              Meetings	Weekly, as agreed
              upon	Progress Meeting (AOR)
	Quarterly In
              Process Review	Every 90 days	Progress Meeting (AOR)
	Final Report	[**] after last
              scheduled delivery	Progress Report (AOR)
	Subcontractor Supply Chain Plans	[**]

              after award	Progress Report (AOR)
	Manufacturing Plan	[**] after award	Progress Report (AOR)
	Distribution Plan	[**] after award	Progress Report (AOR)
	Quality Management Plan	[**] after award	Progress Report (AOR)

   

  Monthly Progress Reports. The Awardee shall submit monthly progress reports no later than the [**] of the
      month. Awardee format acceptable. Electronic submission acceptable in MS Office or PDF format. Financial information shall be MS Excel format. Monthly reports shall NOT be marked proprietary, and shall have Distribution Statement C (US Government and
      their contractors). Each monthly report shall, at a minimum, contain the following:

   

  		●	Summary of monthly progress for each of the Awardee’s facilities/capabilities associated with this effort.

  		●	Summary of progress towards established milestones for each facility/capability.

  		●	Identification of any milestone that is slipping or missed, and discussion of path forward to bring milestone back to
            schedule, and impact on other milestones.

   

  
     

    
      
 

  

   

  		●	Summary of risks, discussion of potential impacts and efforts to mitigate.

  		●	Summary of overall schedule and changes from previous month.

  		●	Status updates from Manufacturing plan

  		●	Status updates from Distribution plan

  		●	Report any customer complaints

  		●	Report any known deficiencies of the materials and/or products

  		●	Financial summary of Awardee deliveries month to date, invoices submitted, and Government payments made.

   

  To the extent trade secret or other proprietary information is relevant to a monthly report, an appropriately
      marked supplement may be provided.

   

  Manufacturing Plan. The Awardee shall provide a detailed plan of action (contractor format acceptable) to
      increase cartridge-manufacturing capability to meet the government’s delivery schedule (i.e. ramp up to 100K cartridges per day) and associated on-shoring component manufacturing within [**] of contract award. The Awardee’s plan of action shall at a
      minimum, include the following:

   

  a.      Timeline, materials required and strategy to set up and begin V2.0 manufacturing lines
      to manufacture the cartridges;

   

  b.      Timeline, materials required and strategy to upgrade the bioproduction capability to
      manufacture sufficient cartridge reagents;

   

  c.      Timeline, materials required and strategy to onshore manufacturing of reagents and
      cartridge subcomponents;

   

  d.      Information on the US based manufacturing organization to replace existing
      organization;

   

  e.      Current GMP manufacturing status and plan to achieve GMP manufacturing, if not
      currently GMP;

   

  f.       Quality Assurance plan and Acceptance metrics;

   

  g.      Plan to comply with FDA EUA Letter of Authorization.

  

   

  Quality Management Plan. Cue Health, Inc. will, in the level of detail and format that Cue Health, Inc.
      solely elects (provided such format provides a reasonable and industry-standard level of detail), provide a quality management plan for manufacturing efforts that conform to ISO 13485 standards as well as the Quality System Regulations at 21 CFR Part
      820 which may include, but is not limited to, the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement,
      and data analysis processes. The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.

   

  
     

    
      
 

  

   

  Distribution Plan. Cue Health, Inc. will, in the level of detail and format that Cue Health, Inc. solely
      elects (provided such format provides a reasonable and industry-standard level of detail), provide a Distribution Plan within [**] of contract award, which shall provide a detailed distribution plan for how all Test Cartridge Packs, Monitoring
      Systems and External Control Swabs Packs will be shipped and delivered to required delivery locations within the United States and its Territories. The Awardee’s distribution plan shall at a minimum, include the following:

   

  

  a.       Current distribution processes;

  b.      Timeline and strategy to increase distribution process and shipping to handle the
      increase in number and volume of shipments.

   

  Subcontractor Supply Chain Plans. Cue Health Inc. will provide plans from key US subcontractors (swab
      manufacturer, fluid transfer automation, etc) describing how they plan to expand their production capacities in support of the Awardee. Cue Health Inc. will describe the source of capital such subcontractors expect to be utilized to increase their
      production rates.

   

  Final Report. Final Report shall NOT be marked proprietary, and shall have Distribution Statement C.

   

  Contractor format acceptable. Electronic submission acceptable in MS Office or PDF format. Financial information
      shall be MS Excel format. Final report summarizing stated objectives and the progress that was achieved in meeting those objectives; summary of risks incurred, impacts and mitigation; quantitative discussion of production throughput improvements
      achieved; financial summary of project; schedule summary for project, comparing original schedule to final schedule; lessons learned for future similar endeavors, and recommendations for path forward as applicable.

   

  		8.	Milestones: Payable milestones under this Agreement are listed in Table 2a and 2b.

   

  Payable Milestones

   

  Table 2a Industrial Expansion Milestones

   

  	Milestone

            #	Milestone

            Description	Due
            Date	Demonstration

            of Milestone	Total Funds
	1	Advance payment for upfront Industrial Expansion costs	Upon award	Award	$184,576,636

   

  Table 2b COVID-19 Test Delivery Milestones*

   

  	 	[**]	[**]	[**]	[**]	[**]	[**]
	Item	Qty	Payment	Qty	Payment	Qty	Payment	Qty	Payment	Qty	Payment	Qty	Payment
	COVID-19 Test Cartridges	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]
	
          Health

          Monitoring Systems

        	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]
	COVID-19 External Control Swab Packs	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]

   

  
     

    
      
 

  

   

  	 	[**]	[**]	[**]	[**]	[**]
	Item	Qty	Payment	Qty	Payment	Qty	Payment	Qty	Payment	Qty	Payment
	COVID-19 Test Cartridges	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]
	Health Monitoring Systems	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]
	COVID-19 External Control Swab Packs	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]	[**]

   

  ARTICLE 2:     TERM AND TERMINATION

   

  		A.	Term of this Agreement

   

  The Term of this Agreement commences upon the Effective Date and extends through final payment. This Agreement is
      anticipated to end 5 months after the Effective Date, subject to mutually agreed extensions pursuant to paragraph 2.D to facilitate the completion of the project(s). A transaction for a prototype project is complete upon the written determination of
      the appropriate official for the matter in question that efforts conducted under a Prototype OT: (1) met the key technical goals of a project, or (2) accomplished a particularly favorable or unexpected result that justifies the completion of the
      prototype.

   

  		B.	Rights of Termination

   

  ●            In the event that Awardee notifies the Government that, as a result of emerging
      safety or efficacy data, no further efforts will be undertaken towards the development of the COVID-19 Test manufacturing and delivery, then, either Party may notify the other Party of its intent to terminate this Agreement, which termination shall
      be effective thirty (30) days after the date of such notice.

   

  ●            Awardee shall have no liability to repay the Government for milestone payments
      made prior to the notification of termination, except as otherwise provided for under Article 14 or Termination for Cause below. With respect to milestones which have not been completed, Awardee shall be entitled to payment based on a percentage of
      the work performed toward said milestones, plus reasonable charges the Awardee can demonstrate to the satisfaction of the Government using its standard record keeping system, have resulted from the termination. By way of example, these costs may
      include, but are not necessarily limited to, costs associated with non-cancellable agreements with vendors to obtain manufacturing capacity or supplies in the performance of this prototype project agreement. Awardee shall not be required to comply
      with the cost accounting standards or contract cost principles for this purpose. This paragraph does not give the Government any right to audit Awardee’s records. Awardee shall not be paid for any work performed which reasonably could have been
      avoided.

   

  
     

    
      
 

  

   

  ●            From and after the effective date of any such termination, Awardee shall have no
      further obligation to deliver any test cartridges, Monitoring Systems or external controls, and the Government shall have no further obligation to accept any such deliverables.

   

  ●            The Government and the Awardee will negotiate in good faith a reasonable and
      timely adjustment of all outstanding issues between the Parties as a result of termination, including disposition of materials acquired for research use. Failure of the Parties to agree to a reasonable adjustment will be resolved pursuant to Article
      7, Disputes. In the event of termination, the Parties shall negotiate in good faith a reasonable wind-down plan and neither Party shall have any continuing obligations to perform under the Program except as otherwise specified herein.

   

  Termination for Convenience: The Government may terminate this Agreement for any or no reason by providing at
      least thirty (30) calendar days’ prior written notice to the Awardee. The Government and Awardee will negotiate in good faith a reasonable and timely adjustment of all outstanding issues between the Parties as a result of termination by the
      Government for convenience, provided that Awardee shall retain all payments for work performed prior to the effective date of the termination consistent with the terms of this Agreement, subject to the Government retaining the right to place Priority
      Orders for up to [**] after the date of such termination, as defined in Article 1, Paragraph C., subparagraph 2., for other diagnostic tests manufactured using the manufacturing equipment purchased with Government funds under this Agreement.

   

  Termination for Cause: If the Awardee materially fails to comply with the provisions of this Agreement, including
      unjustifiably failing to maintain EUA or advance to 510(k) clearance for Awardee’s COVID-19 Test, the Other Transaction Agreement Officer (OTAO), after issuance of a cure notice and failure of the Awardee to cure the defect within [**] or the time
      allowed by the OTAO after Awardee’s receipt of the cure notice, whichever is longer, may take one or more of the following actions as appropriate:

   

  		(i)	temporarily withhold payments pending correction of the deficiency,

  		(ii)	disallow all or part of the price attributable to the activity or action not in compliance,

  		(iii)	wholly or partly suspend or terminate this Agreement,

  		(iv)	withhold further funding, or

  		(v)	take any other legally available remedies.

   

  If this Agreement is terminated for Cause, Awardee will grant the Government a non-exclusive, paid up, perpetual
      license to the Awardee and subawardee patents and documentation necessary for the purpose of developing the Prototype. The Awardee shall provide the Government or its designee with a non-exclusive, paid up, license to any patent, copyright, technical
      data or regulatory information held by the Awardee that relates to the technology to permit the Government to pursue commercialization of the technology with a third party, on terms to be agreed between the Parties and subject to rights granted or
      held by third parties. The terms of this section and the obligations herein will be included in any exclusive license given by the Awardee to a third party for any intellectual property covered by this Agreement, on terms to be agreed between Awardee
      and such third party. This clause will survive the acquisition or merger of the Awardee by or with a third party.

   

  
     

    
      
 

  

   

  In addition to the Government’s remedies prescribed in this Article 2.B, Termination for Cause, after the
      finalization of a termination for default hereunder, where defaulted Awardee has exited or abandoned its business in the Field or has unreasonably abandoned its efforts to maintain EUA or advance to 510(k) clearance for Awardee’s COVID-19 Test, the
      Government may upon [**] written notice to Awardee, take possession of and title to all manufacturing equipment purchased using Government funds provided under this Agreement.

   

  		C.	Survival

   

  In the event of Termination, all rights, obligations, and duties hereunder, which by their nature or by their
      express terms extend beyond the expiration or termination of this Agreement, including but not limited to warranties, indemnifications, intellectual property (including rights to and protection of Intellectual Property and Proprietary Information),
      and product support obligations shall survive the expiration or termination of this Agreement.

   

  		D.	Stop Work Orders

   

  		●	Except as required by applicable law or regulation, or judicial or administrative order, the Government shall not have
            the authority to issue a stop work order to halt the work contemplated under the Statement of Work.

   

  		E.	Extension of Term

   

  The Parties may extend by mutual written agreement the Period of Performance if funding availability and research
      and development or prototype demonstration opportunities reasonably warrant.

   

  ARTICLE 3:     PROJECT MANAGEMENT AND MODIFICATIONS

   

  Technical and project management of the prototype project and associated scope within the Statement of Work shall
      be managed as detailed in this Article.

   

  		A.	Project Governance. Awardee is responsible for the overall management of the
              Prototype Project and related decisions. The Government and Awardee are bound to each other by a duty of good faith in achieving the Prototype Project as defined in Article 1. As such, the Government will have continuous involvement with
              Awardee shall provide project results in accordance with the Deliverables schedule identified in Table 1.

   

  		B.	Project Management. Awardee and the Government will each designate an
              individual responsible for facilitating the communications, reporting, and meetings between the Parties. For Awardee the individual will serve as PM, and for the Government the individual will be the AOR.

   

  
     

    
      
 

  

   

  		C.	Project Reviews. Awardee and the Government will hold periodic project review
              meetings as determined by the Awardee Project Manager and AOR, however, these meetings shall not occur more frequently than every [**].

   

  		D.	Reviews Resulting in Modifications. During the performance of this Prototype
              Agreement, as described above, it may be necessary to modify the scope of the Prototype Project or delivery timeframes. No communications, whether oral or in writing, that purport to change this Agreement are valid unless and until a
              modification is issued by the AO. The Parties hereby agree that any mutually agreed upon written request for modification shall be executed in an expedited timeframe. Modifications to subawards and/or new subcontracts under this Agreement
              that could reasonably impact the technical approach proposed and accepted by the Government require the approval of the AOR prior to being executed.

   

  		E.	Bilateral Modifications. Awardee or the Government may propose modifications to
              this Agreement. A modification that materially changes the obligations of either the Government or Awardee must be in writing and signed by the AO and Awardee authorized official. Awardee requests for modifications shall detail the technical,
              chronological and financial impact of the proposed change on the Statement of Work or delivery timeframes.

   

  		F.	Unilateral Modifications. The AO may ONLY issue minor or administrative
              modifications, which do not change the obligations of Awardee in any adverse manner, such as changes to the paying office or appropriations data, or changes to Government personnel identified in the Agreement. Unilateral modifications will
              only be signed by the AO.

   

  		G.	The AO has assigned an Agreements Officer’s Representative (AOR) for this agreement. The

              Awardee will receive a copy of the written designation outlining the roles and responsibilities of the AOR and specifying the extent of the AOR’s authority to act on behalf of the OTA. The AOR is not authorized to make any commitments or
              changes that will affect price, quality, quantity, delivery, or any other term or condition of the contract.

   

  		H.	Agreement Administration

   

  In no event shall any understanding or agreement, modification, change order, or other matter in
      deviation from the terms of this Agreement between the Awardee and a person other than the AO be effective or binding upon the Government. All such actions must be formalized by a proper contractual document executed by the AO.

   

  Government Points of Contact:

   

  Agreements Officer (AO)

   

  NAME: Vonetta G. McNeal 

    MAILING ADDRESS: 800 Park Office Drive, Research Triangle Park (RTP), NC 27529

   

  
     

    
      
 

  

   

  

    EMAIL: [**]

    PHONE: [**]

    AGENCY NAME/DIVISION/SECTION: Army Contracting Command - Aberdeen Proving Ground - RTP Division

   

  Agreements Officer Representative (AOR)

   

  NAME: [**] 

    MAILING ADDRESS: [**]

    EMAIL: [**]

    PHONE: [**]

   

  Cue Health, Inc. Points of Contact:

   

  Project Manager (PM)

   

  NAME:

      MAILING ADDRESS:

      EMAIL:

      PHONE:

   

  (will be provided within [**] after award)

   

  ARTICLE 4:     MANAGEMENT OF THE PROJECT

   

  		A.	Document Review

   

  		●	The Awardee shall provide the PCT sufficient opportunity to review study protocols, reports, and project plans. PCT’s comments on these documents will be viewed as
            advisory in nature.

   

  B.       Sub-agreement Holders

   

  ●             1. The Government acknowledges that, in order to combat the global
      pandemic and provide the test cartridges, Monitoring Systems and external controls as quickly as possible, Awardee has entered into a number of contracts prior to the Execution Date, and the Government agrees that it will not require these contracts
      to be renegotiated. Therefore, except as otherwise expressly set forth in this Article 4.B, any provision requiring Awardee to flow-down an obligation to its sub-agreement holders will apply only to sub-agreements executed by Awardee following the
      Execution Date of this Agreement.

   

  ●             2. For clarity, as detailed within the Articles themselves, the
      following Articles require flow-down to sub-agreements/contracts executed after the Execution Date:

   

  ●             (i) Article 8: Confidential Information.

   

  
     

    
      
 

  

   

  ●             (ii) Article 13.E: Subawards where the sub-agreement holder may propose
      publishing the results of its work under the subaward.

   

  ●             (iii) The Awardee will flow-down the provisions of Article 19
      (Prohibition on the Use of Certain Telecommunications and Video Surveillance Services or Equipment) to all of its sub-agreements/contracts as provided in Article 19.

   

  ARTICLE 5:     “PREP ACT” COVERAGE

   

  In accordance with the Public Readiness and Emergency Preparedness Act (“PREP Act”), Pub. L. No. 109-148,
      Division C, Section 2, as amended (codified at 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e), as well as the Secretary of Health and Human Service’s (“HHS”) Declaration Under the Public Readiness and Emergency Preparedness Act for Medical
      Countermeasures Against COVID-19, 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012, and on June 8, 2020, 85 Fed. Reg. 34740 (together, the “Prep Act Declaration”):

   

  		(i)	This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution,
            administration, and use of “Covered Countermeasures” for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration;

   

  		(ii)	Awardee performance of this Agreement falls within the scope of the “Recommended Activities” for responding to the
            COVID-19 public health emergency in accordance with Section III of the PREP Act Declaration; and

   

  		(iii)	Awardee is a “Covered Person” per Section V of the PREP Act Declaration.

   

  Therefore, in accordance with Sections IV and VII of the PREP Act Declaration, as well as the PREP Act (42 U.S.C.
      § 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is
      applicable to this Agreement, as long as Awardee activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.

   

  The Government may not use, or authorize the use of, any products or materials provided under this Agreement,
      unless such use occurs in the United States (or a U.S. territory where U.S. law applies including, but not limited to, embassies, military installations and NATO installations) and is protected from liability under a declaration issued under the PREP
      Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope. Any use where the application of the PREP Act is in question will be discussed with Awardee prior to use and, if the Parties disagree on such use, the dispute will be
      resolved according to Article 7, “Disputes.”

   

  ARTICLE 6:     FINANCIAL MATTERS - OBLIGATION AND PAYMENT

   

  This Agreement is fixed-price type Other Transaction Authority agreement. The payments provided under this
      Agreement are intended to compensate the Awardee on a fixed price basis for performance under this Agreement.

   

  
     

    
      
 

  

   

  		A.	Obligation

   

  Except as specified in Article 7: Disputes, the Government’s liability to make payments to the Awardee is limited
      only to those funds obligated under this Agreement or by modification to the Agreement. The ACC-APG Contracting Activity may incrementally fund this Agreement. If modification becomes necessary in performance of this Agreement, pursuant to Article 3
      of this Agreement, the AO and the Awardee shall establish and execute a mutually agreed upon revised Schedule of Payable Milestones consistent with the current SOW.

   

  		B.	Payments

   

  		1.	With the exception of test cartridges, Monitoring Systems and external control packs delivered either to Vendor-managed
            Inventory and/or Government distribution sites for which Government acceptance is detailed in Article 16, Awardee will provide AOR and AO notification of milestone success and any documentation that supports successful completion of the
            milestone. Within [**] of receipt, the AO will either, 1) confirm milestone completion and authorize the Awardee to invoice against the completed milestone or, 2) notify the Awardee of any deficiencies, additional documentation or
            clarifications reasonably needed by the Government to complete its review of the milestone. The Parties agree that payments will be made upon the AOR’s acceptance of completed milestones. These payments reflect value received by the Government
            toward the accomplishment of the Prototype Project goals.

   

  Payments are based on amounts generated from the Awardee’s financial or cost records. The Awardee shall
      be reimbursed for each element identified in the awarded cost proposal, executed and accomplished in accordance with the performance schedule.

   

  		2.	After accomplishment of each milestone, the Awardee will submit the corresponding invoice through a Government provided
            invoicing and payment system, as detailed in Article 18.

   

  		3.	Except as set forth in Article 7, Disputes, in no case shall the Government’s financial liability exceed the amount
            obligated under this Agreement.

   

  		4.	Payments will be made by the cognizant Defense Finance and Accounting Services office, as indicated below, in accordance
            with the Prompt Payment Act. Article 18 details how to submit and process invoices.

   

  		5.	Payments shall be made in the amounts set forth in the SOW, provided the AOR has verified the completion of the
            applicable milestones. The Government will pay Awardee in US dollars.

   

  		6.	The amounts payable by the Government to the Awardee pursuant to this Agreement shall not be reduced on account of any
            Taxes unless required by applicable law. The Awardee alone shall be responsible for paying any and all Taxes (other than withholding Taxes required to be paid by the Government under applicable law) levied on account of, or measured in whole or
            in part by reference to, any payments it receives. If the Awardee is entitled under any applicable Tax treaty to a reduction of rate of, or the elimination of, or recovery of, applicable withholding Tax, it shall deliver to the Government or
            the appropriate governmental authority (with the assistance of the Government to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or
            to relieve the Government of its obligation to withhold Tax, and the Government shall apply the reduced rate of withholding, or dispense with the withholding, as the case may be, to the extent it complies with the applicable Tax treaty. If, in
            accordance with the foregoing, the Government withholds any amount, it shall make timely payment to the proper Taxing Authority of the withheld amount, and send to the Awardee proof of such payment within 90 days following that payment.

   

  
     

    
      
 

  

   

  As used herein: Taxes means all taxes of any kind, and all charges, fees, customs, levies, duties,
      imposts, required deposits or other assessments, including all federal, state, local or foreign net income, capital gains, gross income, gross receipt, property, franchise, sales, use, excise, withholding, payroll, employment, social security,
      worker’s compensation, unemployment, occupation, capital stock, transfer, gains, windfall profits, net worth, asset, transaction and other taxes, and any interest, penalties or additions to tax with respect thereto, imposed upon any person by any
      Taxing Authority or other governmental authority under applicable law, whether disputed or not, and including any obligation to indemnify or otherwise assume or succeed to the Tax liability of any other person by law, by contract or otherwise. Taxing

        Authority means any governmental authority or any subdivision, agency, commission or authority thereof or any quasi-governmental body exercising tax regulatory authority.

   

  		7.	The Awardee shall maintain adequate records to account for all funding under this Agreement. Neither the Cost Accounting
            Standards nor any other aspect of the Federal Acquisition Regulation or its supplements apply to Awardee’s accounting of costs under this Agreement. Cost shall be accounted for in accordance with Awardee’s commercial accounting practices.
            Awardee has an established and agrees to maintain an established accounting system which complies with Financial Reporting Standards and the requirements of this Agreement, and shall ensure that appropriate arrangements have been made for
            receiving, distributing and accounting for Federal funds. An acceptable accounting system is one in which all costs, cash receipts and disbursements for which Awardee is entitled to reimbursement under Article 6 are controlled and documented
            properly.

   

  A.           Obligation. Under no circumstances shall the Government’s financial
      obligation exceed the amount obligated in this Agreement or by amendment to the Agreement. The amount of Government funds obligated by this Agreement and available for Payment is set forth on page 1, Line of Accounting and Appropriation. The
      Government may incrementally fund this agreement.

   

  B.            The Government is not obligated to provide payment to the Awardee for
      amounts in excess of the amount of obligated funds allotted by the Government.

   

  C.            The Government shall pay the Awardee, upon submission of proper
      invoices, the costs stipulated in this Agreement for work delivered or rendered and accepted, less any deductions provided in this Agreement. Unless otherwise specified, payment shall be made upon acceptance of any portion of the work delivered or
      rendered for which a price is separately stated in the Agreement. Payments will be made within [**] of receipt of a request for payment.

   

  
     

    
      
 

  

   

  D.           Prior written approval by the AO, or the AOR, is required for all travel
      directly and identifiably funded by the Government under this agreement. The Awardee shall present to the AO or AOR, an itinerary for each planned trip, showing the name of the traveler, purpose of the trip, origin/destination, dates of travel, and
      estimated cost broken down by line item as far in advanced of the proposed travel as possible, but no less than [**] before travel is planned to commence. In the event that emergency travel is required (e.g. in the event of an outbreak) that would
      make two weeks’ notice impractical, travel requests may be submitted to the Government for an expedited review. Emergency travel requests shall be labelled as such and shall include a brief summary of the emergency situation and rationale for
      expedited review.

   

  E.            WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (MAY 2013)

   

  (a)           Definitions. As used in this clause-

   

  Department of Defense Activity Address Code (DoDAAC) is a six position code that uniquely identifies a
      unit, activity, or organization.

   

  Document type means the type of payment request or receiving report available for creation in Wide Area
      WorkFlow (WAWF).

   

  Local processing office (LPO) is the office responsible for payment certification when payment
      certification is done external to the entitlement system.

   

  (b)          Electronic invoicing. The WAWF system is the method to electronically
      process vendor payment requests and receiving reports, as authorized by DFARS 252.232-7003, Electronic Submission of Payment requests and Receiving Reports.

   

  (c)          WAWF access. To access WAWF, the Awardee shall (i) have a designated
      electronic business point of contact in the System for Award Management at https://www.acquisition.gov; and (ii) be registered to use WAWF at https://wawf.eb.mil/ following the step-by-step procedures for self-registration available at this website.

   

  (d)          WAWF training. The Awardee should follow the training instructions of
      the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF. Both can be accessed by selecting the “Web Based Training” link on the WAWF home page at https://wawf.eb.mil/.

   

  (e)           WAWF methods of document submission. Document submissions may be via
      Web entry, Electronic Data Interchange, or File Transfer Protocol.

   

  (f)           WAWF payment instructions. The Awardee must use the following
      information when submitting payment requests and receiving reports in WAWF for this Agreement:

   

  
     

    
      
 

  

   

  (1)           Document type. The Awardee shall use the following document type:
      Voucher

   

  (2)           Inspection/acceptance location. The Awardee shall select the following
      inspection/acceptance location(s) in WAWF, as specified by the contracting officer.

   

  (3)           Document routing. The Awardee shall use the information in the Routing
      Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.

   

  Routing Data Table

   

  	Field Name in WAWF	Data to be entered in WAWF
	Pay

            Official DoDAAC	HQ0339
	Issue

            By DoDAAC	W911NF
	Admin

            DoDAAC	S0514A
	Inspect By DoDAAC	W56XNH

   

  (4)           Payment request and supporting documentation. The Awardee shall ensure
      a payment request includes appropriate contract line item and subline item descriptions of the work performed or supplies delivered, costs, fee (if applicable), and all relevant back-up documentation In support of each payment request.

   

  (5)           WAWF email notifications. The Awardee shall enter the email address
      identified below in the “Send Additional Email Notifications” field of WAWF once a document is submitted in the system.

   

  AO: [**]

      AOR: [**]

   

  (g)           WAWF point of contact.

   

  (1)           The Awardee may obtain clarification regarding invoicing in WAWF from
      the following contracting activity’s WAWF point of contact.

   

  (2)           For technical WAWF help, contact the WAWF helpdesk at 866-618-5988.

      (End of Clause)

   

  1. The AOR identified in Supplement 4, “Agreement Administration” shall continue to formally inspect
      and accept the deliverables/milestones. To the maximum extent practicable, the AOR shall review the deliverable(s) milestone report(s) and either:

   

  i. provide a written notice of rejection to the Awardee which includes feedback regarding deficiencies
      requiring correction or

   

  ii. written notice of acceptance to the AO, and acceptance in the WAWF system.

   

  2. Acceptance within the WAWF system shall be performed by the AOR.

   

  
     

    
      
 

  

   

  Note for DFAS: The Agreement shall be entered into the DFAS system by CLIN -
      Milestone association (MS)/ACRN as delineated in Section B of the Award. The Agreement is to be paid out by CLIN (MS)/ACRN. Payments shall be made using the CLIN (MS)/ACRN association as delineated at Section B of this Award.

   

  Awardee Information: As identified at Central Contractor Registration, i.e.,
      Commercial and Government Entity (CAGE) Code, Dun & Bradstreet number (DUNS), and Tax Identification Number (TIN). Payments shall be made in the amounts set forth in the SOW, provided the AOR has verified the completion of the milestones.

   

  F.            Comptroller General Access to Records: To the extent that the total
      Government payments under this Agreement exceed $5,000,000, the Comptroller General, at its discretion, shall have access to and the right to examine records of any Party to the Agreement or any entity that participates in the performance of this
      Agreement that directly pertain to, and involve transactions relating to, the Agreement for a period of three (3) years after final payment is made. This requirement shall not apply with respect to any Party to this Agreement or any entity that
      participates in the performance of the Agreement, or any subordinate element of such Party or entity, that has not entered into any other agreement (contract, grant, cooperative agreement, or “other transaction”) that provides for audit access by a
      government entity in the year prior to the date of this Agreement. This paragraph only applies to any record that is created or maintained in the ordinary course of business or pursuant to a provision of law. The terms of this paragraph shall be
      included in all sub-agreements to the Agreement other than sub-agreements with a component of the U.S. Government. The Comptroller General may not examine records pursuant to a clause included in an agreement more than three years after the final
      payment is made by the United States under the agreement.

   

  		C.	Comptroller Access Financial Records and Reports:

   

  Awardee shall maintain adequate records to account for Federal funds received under this Agreement and shall
      maintain adequate records to account for funding provided under this Agreement. Awardee relevant financial records are subject to examination or audit by or on behalf of the Comptroller General, Contracting Activity AO, or other Government Official
      for a period not to exceed three (3) years after expiration of the term of the Agreement. The Comptroller General, AO or designee shall have direct access to sufficient records and information of any party to this agreement or any entity that
      participates in the performance of this agreement to ensure full accountability for all funding under this Agreement. Such audit, examination or access shall be performed during business hours on business days upon prior written notice and shall be
      subject to the security requirements of the audited party. Any audit required during the course of the program may be conducted by the Comptroller General or other Government Official using Government auditors or, at the request of Awardee’s external
      CPA accounting firm at the expense of the Awardee.

   

  		1.	Lower Tier Agreements

   

  The Performer shall include this Article, suitably modified to identify the Parties, in all subcontracts or lower
      tier agreements entered into solely in connection with this Agreement.

   

  
     

    
      
 

  

   

  ARTICLE 7:     DISPUTES

   

  		A.	General

   

  The Parties shall communicate with one another in good faith and in a timely, responsive, and cooperative manner
      when raising issues under this Article.

   

  		B.	Dispute Resolution Procedures

   

  		1.	Any claim or dispute between the Government and Awardee concerning questions of fact or law arising from or in connection
            with this Agreement, and, whether or not involving an alleged breach of this Agreement, shall be raised and resolved under this Article.

   

  		2.	Whenever legal disputes or claims arise, the Parties shall attempt to resolve the issue(s) by discussion and come to
            mutual agreement on a resolution as soon as practicable. In no event shall a dispute, disagreement or misunderstanding of which the aggrieved Party became aware more than [**] prior to the notification made under sub-section B.3 of this Article
            constitute the basis for relief under this Article unless one level above the AO, in the interests of justice, waives this requirement.

   

  		3.	Failing resolution by mutual agreement, the aggrieved Party shall document the dispute, disagreement, or misunderstanding
            by notifying the other Party (through the AO Awardee s POC, as the case may be) in writing of the relevant facts, identifying unresolved issues, and specifying the clarification or remedy sought. Within [**] after providing notice to the other
            Party, the aggrieved Party may, in writing, request a joint decision by the ACC-APG Division Chief for and senior executive appointed by Awardee The other Party shall submit a written response on the matter(s) in dispute within [**] after being
            notified that a decision has been requested. The Division Chief and the Awardee senior executive shall conduct a review of the matter(s) in dispute and attempt to render a mutually agreeable decision in writing within [**] of receipt of such
            written position. Any such joint decision is final and binding.

   

  		4.	In the absence of a joint decision, upon written request to the ACC-APG Associate Director made within [**] of the
            expiration of the time for a decision under sub-section B.3 above, the dispute shall be further reviewed. The Associate Director may elect to conduct this review personally or through a designee or jointly with a senior executive appointed by
            Awardee Following the review, the Associate Director or designee will resolve the issue(s) and notify the Parties in writing. This decision may be appealed to any federal court of competent jurisdiction.

   

  		5.	Notwithstanding any other provisions of this Article, the Parties agree that Awardee shall have the right to pursue any
            contract dispute arising under this Agreement in any federal court of competent jurisdiction, including the appropriate Court of Appeals, or the Supreme Court, at any time without any administrative exhaustion requirements, and the timing
            requirements described above will not limit any claim in such tribunals.

   

  
     

    
      
 

  

   

  		C.	Limitation of Damages

   

  Claims for damages of any nature whatsoever pursued under this Agreement shall be limited to direct damages only
      up to the aggregate amount of Government funding obligated as of the time the dispute arises, except with respect to violations of Articles 5, 8, 9, or 10 of this Agreement.

   

  ARTICLE 8:     CONFIDENTIAL INFORMATION

   

  		A.	“Confidential Information,” as used in this Article, means information or data
              of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.

   

  		B.	The Agreements Officer and the Awardee may, by mutual consent, identify elsewhere in this Agreement
            specific information and/or categories of information which the Government will furnish to the Awardee or that the Awardee is expected to generate which is confidential. Similarly, the Agreements Officer and the Awardee may, by mutual consent,
            identify such Confidential Information from time to time during the Period of Performance. Failure to agree will be settled pursuant to the “Disputes” clause.

   

  		C.	If it is established elsewhere in this Agreement that information to be utilized under this
            Agreement, or a portion thereof, is subject to the Privacy Act, the Awardee will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. § 552a, and implementing regulations and policies, with respect to
            systems of records determined to be subject to the Privacy Act.

   

  		D.	The Receiving Party shall not directly or indirectly, divulge or reveal to any person or entity any
            Confidential Information of another Party without the Disclosing Party’s prior written consent, or use such Confidential Information except as permitted under this Agreement. Confidential Information shall be subject to the same prohibitions on
            disclosure as provided for under FAR Part 24.202. Further, any reproduction of Confidential Information or portions thereof that is disseminated within the Government, CMF, or Awardee, shall be shared strictly on a need to know basis for the
            purposes of this Agreement and is subject to the restrictions of this provision. In addition to the above, Confidential Information is subject to the protections of the Trade Secrets Act as well as any other remedies available under this
            Agreement or the law.

   

  		E.	Such obligation of confidentiality shall not apply to information which the Receiving Party can
            demonstrate through competent evidence: (i) was at the time of disclosure in the public domain; (ii) has come into the public domain after disclosure through no breach of this contract; (iii) was known to the Receiving Party prior to disclosure
            thereof by the Disclosing Party; (iv) was lawfully disclosed to the Receiving Party by a Third Party which was not under an obligation of confidence to the Disclosing Party with respect thereto; or (v) was approved for public release by prior
            written permission of the Disclosing Party.

   

  
     

    
      
 

  

   

  		F.	Whenever the Awardee is uncertain with regard to the proper handling of material under the
            Agreement, or if the material in question is subject to the Privacy Act or is Confidential Information subject to the provisions of this Article, the Awardee shall obtain a written determination from the Agreements Officer prior to any release,
            disclosure, dissemination, or publication.

   

  		G.	Agreements Officer Determinations will reflect the result of internal coordination with appropriate
            program and legal officials.

   

  		H.	The provisions of paragraph (D) of this Article shall not supersede conflicting or overlapping
            provisions applicable Federal, State or local laws.

   

  		I.	The obligations of the Receiving Party under this Article shall continue for a period of [**] from
            conveyance of the Confidential Information.

   

  Subject to Article 4.B, all above requirements MUST be passed to all Sub-awards.

   

  ARTICLE 9:     INTELLECTUAL PROPERTY RIGHTS

   

  		A.	Awardee represents that, to its knowledge, the intellectual property license(s) and other rights
            held by or granted to Awardee, are sufficient to enable Awardee to perform its obligations under this Agreement.

   

  		B.	Background IP and Materials. Awardee and the Government each retain any
              intellectual property (IP) rights to their own materials, technical data (as defined in 48 DFARS 252.227-7013), technology, information, documents, or Know-How—or potential rights, such as issued patents, patent applications, invention
              disclosures, copyrighted works, or other written documentation—that exist prior to execution of this Agreement or are developed outside the scope of this Agreement (“Background IP”). For avoidance of
              confusion, Background IP includes but is not limited to Background Inventions. Awardee agrees to provide, within [**] of the effective date of this Agreement, a list of all Background Inventions relevant to Awardee’s performance of the
              prototype project. Any material defect identified in the Background Invention disclosure that could materially negatively impact performance of the prototype project, will be addressed between the AOR and the Awardee’s designee.

   

  		C.	Government’s Background IP. The Government has Background IP as constituted
              under contract number HHSO100201800016C, including all executed modifications.

   

  		D.	Agreement Inventions. In the unlikely event that an invention is conceived or
              first actually reduced to practice in the performance of this Agreement (“Agreement Invention”), ownership of any Agreement Invention, regardless of whether it is not patentable, or is patentable under U.S. patent law that is conceived or
              first reduced to practice under this Agreement will follow inventorship in accordance with U.S. patent law. Neither the Government nor Awardee anticipate the conception or reduction to practice of any Agreement Invention. The Government
              acknowledges that in the absence of any Agreement Invention, the Bayh-Dole Act (35 U.S.C. §§ 200-212) does not apply to, nor govern, this Agreement. Since, in the absence of any Agreement Invention, the Bayh-Dole Act, does not apply to this
              Agreement, as such, title to Agreement Invention will accrue to the inventor or inventor-organization. In the absence of any Agreement Invention, the Government shall not have any rights to “march-in,” as that term is defined in 35 U.S.C. §
              203, and Awardee is not subject to the manufacturing requirements of 35 U.S.C. § 204.

   

  
     

    
      
 

  

   

  In the event an Agreement Invention arises, the Parties represent and warrant that each inventor will
      assign his or her rights in any such Agreement Inventions to his or her employing organization. If an Agreement Invention is made either by a Awardee employee (“Sole Recipient Agreement Invention”) or made by a Government employee (“Sole
        Government Agreement Invention”) the entire rights to that sole Awardee Agreement Invention or Sole Government Agreement Invention will be respectively assigned to the Awardee or to the Government. If an Awardee employee and a Government
      employee jointly make an Agreement invention (“Joint Agreement Invention”), it will be owned jointly by the Awardee and the Government. Ownership of inventions made in whole or in part with sub-Awardee or collaborator employees, including
      employees of other components of the Government, will be determined solely pursuant to an agreement between the Awardee and the applicable sub-Awardee or collaborator. Notwithstanding the foregoing, neither the Government nor Awardee anticipate the
      Government making a Sole Government Agreement Invention, nor the Parties jointly making a Joint Agreement Invention, as Awardee employees are solely responsible, as between the Parties, for performing the Prototype Project under this Agreement.

   

  		E.	Patent Applications. Each Party shall report any Agreement Inventions to the
              other Party within [**] of the time the inventor discloses it in writing to its personnel responsible for patent matters. The Parties will respectively have the option, in their discretion, to file a patent application claiming any Agreement
              Invention made solely by their respective employees (but, for clarity, are not obligated to file patent applications claiming any Agreement Invention, and will not forfeit title by electing to hold an Agreement Invention as a trade secret).
              The Parties will consult with each other regarding the options for filing a patent application claiming a joint Agreement Invention. Within [**] of being notified of the discovery of an Agreement Invention, each Party will provide notice of
              any filing of a patent application to the other Party. The Parties will reasonably cooperate with each other in the preparation, filing, and prosecution of any patent application claiming a Joint Agreement Invention. Any Party filing a patent
              application will bear expenses associated with filing and prosecuting the application, as well as maintaining any patents that issue from the application, unless otherwise agreed by the Parties. Executive Order No. 9424 of 18 February 1944
              requires all executive Departments and agencies of the Government to forward through appropriate channels to the Commissioner of Patents and Trademarks, for recording, all Government interests in patents or applications for patents.

   

  		F.	Patent Prosecution. Awardee agrees to take responsibility for the preparation,
              filing, prosecution, and maintenance of any and all patents and patent applications that are relevant to the work performed under this Agreement. Awardee shall keep the Government reasonably advised on the status of Awardee Background IP by
              providing an annual report on the status of Awardee Background IP. With respect to a Sole Awardee Agreement Invention or a Joint Agreement Invention, prior to acting on a decision by Awardee to abandon or not file in any country a patent or
              patent application covering a Sole Awardee Agreement Invention or a Joint Agreement Invention, Awardee shall so inform the Government in a timely manner to allow Awardee to thoughtfully consider the Government’s comments regarding such a
              proposed decision.

   

  
     

    
      
 

  

   

  If the Licensor shall continue the prosecution of any application for, to pay the maintenance fees on,
      or defend in reexamination or opposition proceedings on, a Joint Agreement Invention on behalf of Awardee, Awardee shall notify the Government within [**]. If the Licensor notifies Awardee that it declines to continue prosecution of any application
      for, to pay the maintenance fees on, or defend in reexamination or opposition proceedings on, a Joint Agreement Invention, Awardee shall notify the Government within [**] after receipt of such notice.

   

  		G.	Patent Enforcement. Awardee will have the first option to enforce any patent
              rights covering a Joint Agreement Invention at Awardee’s expense. If Awardee chooses not to exercise this option, the Government may enforce patent rights covering a Joint Agreement Invention.

   

  		H.	Licenses.

   

  Background IP. The Government has the rights in Background IP constituted under contract number
      HHSO100201800016C, including all executed modifications.

   

  Agreement Inventions. Any Sole Awardee Agreement Invention is subject to a nonexclusive,
      nontransferable, irrevocable, paid-up license for the Government, to practice and have practiced the Agreement Invention on behalf of the Government. For any Sole Government Agreement Invention, upon the Awardee’s request, the Government agrees to
      enter into good faith negotiations with the Awardee regarding the Awardee’s receipt of a nonexclusive commercialization license covering the Government’s interest in any Sole Government Agreement Invention.

   

  ARTICLE 10:       DATA RIGHTS

   

  		A.	Background Data. “Background Data” shall mean all data, that exists prior to
              execution of this Agreement, or are developed outside the scope of this Agreement. Awardee’s Background Data includes, but is not limited to, the following technical data, to the extent such data exists prior to execution of this
                Agreement or is developed outside the scope of this Agreement:

   

  		1.	Technical data as defined at DFARS 252.227-7013 (“Technical Data”),

  		2.	All data relating to the development, commercialization, manufacture of the test kits,

  		3.	All data relating to the manufacturing, quality control testing (including in-process, release and stability testing),
            processing, releasing, or packaging of the test kits; and

  		4.	Any and all data relating to preparatory work for distributing, importing, exporting, selling, offering for sale,
            supplying, offering for supply or otherwise exploiting the Awardee COVID 19 tests.

   

  
     

    
      
 

  

   

  All Background Data shall be owned by the Awardee, subject to the Government’s rights in Background Data
      developed or produced in the performance of contract number HHSO100201800016C, including all executed modifications thereto. Awardee hereby grants the Government a non-exclusive license subject to the limitations specified in Article 10.C to use any
      Background Data, other than clinical data, or financial, administrative, cost, pricing or management information, solely to the extent necessary for the Government to perform its obligations under this Agreement and meet its objective of facilitating
      administration of the COVID-19 Tests delivered under this Agreement in accordance with FDA and other applicable regulations.

   

  		B.	Subject Data. “Subject Data” is defined as all Technical Data generated by or
              on behalf of Awardee in the performance of this Agreement. Subject Data shall be owned by the Awardee. The Government shall obtain “Unlimited rights”, as this term is defined in DFARS 252.227-7013(a)(16) in Subject Data specified for delivery
              under this Agreement and Government Purpose Rights, as the term is defined in DFARS 252.227-7013(a)(13), in Subject Data not specified for delivery under this Agreement. . The Awardee agrees to retain and maintain in a clear and readable
              manner, until [**] after completion or termination of this Agreement, all Subject Data.

   

  		C.	Restrictions on Government License Rights. Subject to the Government’s
              pre-existing rights under contract HHSO100201800016C as modified:

   

  		a.	Background Data other than computer software in which the Government has rights under Article 10. A shall be received by
            the Government subject to Limited Rights as defined at DFARS 252.227-7013.

   

  		b.	Background Data that is computer software in which the Government has rights under Article 10.A shall be received by
            Government subject to Restricted Rights as defined at DFARS 252.227-7014, except that the Government shall instead receive commercial software license rights in such software that is a commercial item as defined at FAR 2.101.

   

  		D.	Marking of Data. The Awardee will mark any Data delivered under this Agreement
              with the following legend:

   

  “Use, duplication, or disclosure is subject to the restrictions as stated in Agreement No.
      W911NF-21-9-0001 between the Government and the Awardee.”

   

  The Awardee may further mark Data furnished with the rights specified in Article 10.C as “Limited
      Rights Data,” “Restricted Rights Software,” or “Commercial-Rights Software,” as appropriate. Any rights that the Awardee or the Government may have in Data delivered under this Agreement, whether arising under this Agreement or otherwise, will not be
      affected by Awardee’s failure to mark Data pursuant to this Article.

   

  All Subject Data, Technical Data and Software (each term as defined under DFARS 252.227-7013) which
      shall be delivered under this Agreement with less than Unlimited Rights shall be identified in reasonable specificity and particular rights granted (Government Purpose, Limited or Restricted (all as defined in DFARS 252.227-7013)). If the data is
      marked “Limited Rights”, the Awardee shall provide, upon request by the Government, an explanation to the Government as to why the data does not fall within the deliverables, and thus should not be accorded Unlimited Rights status.

   

  
     

    
      
 

  

   

  ARTICLE 11:       REGULATORY RIGHTS

   

  The Awardee shall provide the Government with all material communications and summaries thereof, both
      formal and informal, to or from FDA, regarding the Awardee’s EUA for its COVID-19 Test or the prototype project within [**], and make best efforts to ensure that the Government representatives are invited to participate in any formal or informal
      meetings with FDA. Awardee shall (1) ensure that the Government representatives are consulted and are invited to participate in any formal or informal meetings with FDA related to Awardee’s COVID-19 Test and the prototype project; and (2) notify the
      FDA that the Government has the right to discuss with FDA any development efforts regarding the prototype project. In addition to the foregoing, Awardee shall use diligent efforts to notify the Government within [**] of any event, risk, formal or
      informal FDA communication, or other issue that would be reasonably expected to materially impact the Awardee’s EUA For the COIVD-19 Test or ability to advance to final 510(k) clearance of the Awardee’s COVID-19 Test.

   

  ARTICLE 12:       FOREIGN ACCESS TO DATA

   

  		A.	The Parties will comply with any applicable U.S. export control statutes and regulations in
            performing this Agreement.

   

  ARTICLE 13:       SCIENTIFIC PUBLICATIONS AND PRESS RELEASES

   

  		A.	Neither Awardee nor the Government shall make, or permit any person to make, any public announcement
            concerning the existence, subject matter or terms of this Agreement, the transactions contemplated by it, or the relationship between the Awardee and the Government hereunder, without the prior written consent of the other, such consent not to
            be unreasonably withheld or delayed, except as required by law, any governmental or regulatory authority (including, without limitation, any relevant securities exchange), any court or other authority of competent jurisdiction.

   

  		B.	Notwithstanding the foregoing, Awardee and (its upstream licensor) retains the right, but not the
            obligation, to prepare and submit scientific publications and release information to the public about its COVID-19 development program, without the Government’s consent or involvement. The Awardee shall inform the AOR when any abstract article
            or other publication is published, and furnish a copy of it as finally published.

   

  		C.	Unless authorized in writing by the AO, the Awardee shall not display Government logos including
            Operating Division or Staff Division logos on any publications.

   

  		D.	The Awardee shall not reference the products(s) or services(s) awarded under this contract in
            commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies Government approval or endorsement of the product(s) or service(s) provided.

   

  
     

    
      
 

  

   

  		E.	Subject to Article 4.B, the Awardee shall include this clause, including this section (d) in all
            subawards where the sub-agreement holder may propose publishing the results of its work under the subaward. The Awardee shall acknowledge the support of the Government whenever publicizing the work under this Agreement in any written media by
            including an acknowledgement substantially as follows:

   

  “This project has been funded in whole or in part by the U.S. Government under Agreement No.
      W911NF-21-9-00XX. The US Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon.”

   

  ARTICLE 14:       ENSURING SUFFICIENT SUPPLY OF THE PRODUCT

   

  		A.	In recognition of the Government’s significant funding for the development and manufacturing of the
            COVID- 19 Test and the Government’s need to provide sufficient quantities of a COVID-19 tests to protect the United States population, the Government shall have the remedy described in this section to ensure sufficient supply of test kits to
            meet the needs of the public health or national security. This remedy is not available to the Government unless and until any of the following conditions is met, and is not available as a result of a termination under Article 2(B) of this
            Agreement:

   

  		i.	Awardee gives notice, required to be submitted to the Government no later than [**], following any formal management
            decision to terminate the product development effort, including a decision not to maintain EUA or proceed to 510(k) clearance during the term of this Agreement or [**] thereafter;

   

  		ii.	Awardee gives written notice, required to be submitted to the Government no later than [**], of any filing that
            anticipates Federal bankruptcy protection during the term of this Agreement or [**] thereafter.

   

  		B.	If one or more of the conditions listed in Section 14.A occurs, Awardee, upon the request of the
            Government, subject to the terms of the pre-existing agreement with Licensor, shall provide the following items necessary for the Government to pursue licensure/authorization and manufacturing of the Technology with a third party for exclusive
            sale to the U.S. Government:

   

  		i.	a writing evidencing a non-exclusive, nontransferable, irrevocable (except for cause), royalty-free paid-up license to
            practice or have practiced for or on behalf of the U.S. Government any Awardee Background IP and Background Data, as those terms are defined in of this Agreement, necessary to manufacture or have manufactured the Technology;

   

  		ii.	any outstanding Deliverables contemplated or materials and possession of and title to manufacturing equipment purchased
            with Government funds under this Agreement.

   

  		C.	This Article will survive the acquisition or merger of the Awardee by or with a third party. This
            Article will survive the expiration of this agreement.

   

  
     

    
      
 

  

   

  ARTICLE 15:       ARTICLE 15: INSPECTION AND ACCEPTANCE

   

  		A.	Delivery and Acceptance. Awardee shall notify the AO and AOR at least [**]
              prior to initial delivery of first shipment of test kits. Exceptions are permitted if approved by the AO. Upon notification, the AOR will instruct the Awardee to deliver kits to either up to three centralized Government-designated
              distribution sites within the continental United States or up to three additional specific individual final destinations within the continental United States. Upon delivery of product, notification of delivery quantities shall be made to the
              AOR.

   

  Upon receipt of the provided certificates and any inspection of product at the origin or destination
      site(s) that was timely requested (physical or representative, i.e., pictures), the AOR will review and recommend acceptance or rejection. The Government shall accept product that conforms to contract requirements based on Certificates of Analysis
      and certificate(s) of cGMP conformity provided by Awardee and review of temperature monitoring data. The AO will correspondingly notify Awardee of acceptance or rejection. However, the Government’s acceptance of product will be deemed to have
      occurred if the Government does not provide written notice of acceptance or rejection within [**] of Awardee’s provision of all applicable certificates.

   

  A. Inspection: The Government has the right to inspect and test all work called for by this Agreement,
      to the extent practicable at all places and times, including the period of performance, and in any event before acceptance. The Government may also inspect the premises of the Awardee. The Government shall perform inspections and tests in a manner
      that will not unduly delay the work. If the Government performs any inspection or test on the premises of the Awardee, the Awardee shall furnish, at no increase in price, all reasonable facilities and assistance for the safe and convenient
      performance of these duties. Except as otherwise provided in the Agreement, the Government shall bear the expense of Government inspections or tests made at other than the Awardee’s premises.

   

  B. The Government shall inspect/accept or reject the work as promptly as practicable after
      completion/delivery, unless otherwise specified in the Agreement. Government failure to inspect and accept or reject the work shall not relieve the Awardee from responsibility, nor impose liability on the Government, for nonconforming work. Work is
      nonconforming when it is defective in material or workmanship or is otherwise not in conformity with Agreement requirements. The Government has the right to reject nonconforming work. Inspection/Acceptance of the Prototype performed should not exceed
      [**] after completion.

   

  		B.	Vendor-managed Inventory. Product to be stored as VMI will be shipped to
              Awardee’s own warehouse locations or its third party vendor’s site, and may be stored for a period not longer than [**]. Prior to expiration of this [**] period, the Government must either (a) provide Awardee with disposition instructions in
              sufficient time to transfer and take possession of physical material from Awardee, (b) bilaterally modify this agreement to extend the period of vendor management of storage, or (c) bilaterally modify this Agreement to include destruction of
              remaining doses.

   

  
     

    
      
 

  

   

  When held in VMI, these materials will be maintained in Awardee’s or its designated representative’s
      quality and inventory systems. Product held in VMI is subject to the following requirements:

   

  		i.	Provide temperature controlled storage at the manufacturer’s site approved by the Government, according to cGMP and
            product specifications.

  		ii.	Where possible, store Project Agreement products physically segregated from other products. If physical separation is not
            possible, separation of Project Agreement products must be controlled by a logical warehouse management system (WMS) at the case and pallet level.

  		iii.	Ensure proper labeling of stored materials as USG property.

  		iv.	Provide the Government access to review the security systems in place and request updates as needed in accordance with
            the Security Plan.

  		v.	Make appropriate updates to the regulatory documentation supporting the continued use of the stored material for pandemic
            response.

  		vi.	If using a storage site, provide the quality agreement, specify the location and terms of the storage contract and
            receive approval by the Government.

   

  For accepted product in VMI, Awardee must notify the AOR of any proposed movement of the product. Any
      deviations, out of specification (“OOS”) results, or other product issues, shall be reported to the USG within [**] of Awardee identification.

   

  		C.	Government Sites. Product to be shipped to Government Sites shall be shipped
              trackable by GPS. Awardee will include the following information on the packing lists provided with bulk shipments to the centralized depots:

   

  		i.	Transaction Information (TI)

  		ii.	Transaction History (TH)

  		iii.	Transaction Statement (TS)

   

  		D.	Title and Physical Risk of Loss. Risk of loss or damage to the supplies
              provided under this contract shall remain with the Contractor until, and shall pass to the Government upon delivery of the supplies to the Government at the destination specified in the contract, i.e., F.O.B. Destination.

   

  Awardee will notify the AO and AOR of any storage or quality deviation for product held in VMI, within
      [**]. To the extent that Awardee is responsible for the correction, repair or replacement of Government property held in VMI and replacement upon loss or damage is feasible, the Government will accept replacement of such property. The Government
      understands that storage costs identified in this contract include insurance costs applicable to material that will become Government property, including product stored as VMI.

   

  The AO and/or the AOR may perform inspection of materials and services. Inspections of material created
      under this Project Agreement may be made by a duly authorized Government representative, and with reasonable notice.

   

  
     

    
      
 

  

   

  		E.	Risk of Loss Due to Expiry. Both parties acknowledge that risk of loss due to
              expiry is retained by the Government for all product accepted under this Agreement. In order to mitigate this risk, the Awardee will make kits available for delivery to VMI or Government distribution sites within [**] of the date of
              manufacture. Provided this condition is met, the Awardee will have no obligation to replace product that has been accepted by the Government and expires prior to use.

   

  ARTICLE 16:       ARTICLE 16: REPORTING REQUIREMENTS

   

  The Government will have continuous involvement with Awardee throughout the duration of the Period of Performance
      and is entitled to periodic reports as outlined below. Required components and frequency of such reporting is as follows:

   

  		A.	Weekly Progress Meetings: Scheduled on a weekly basis, virtual format (either
              telephone or videoconference), between the Contractor and the Government. Duration: [**] max. Review of previous weeks activities. Informative in nature to keep the USG apprised of project progress and to discuss issues that may require joint
              resolution, such as milestone changes, political impacts on objectives, schedule, funding and deliverables.

   

  On a quarterly basis, at the request of the AOR, the Weekly Teleconference may be expanded in scope to allow for
      a progress review of the preceding three months and planning for the remainder of the period of performance.

   

  		B.	Daily and Ad hoc check-in, as requested by the PCT: A program specific designee
              of the Awardee will hold a daily check-in with the AOR or AOR designee to discuss the performance of the Agreement. No agenda, presentation, or official minutes need to be maintained for the regular meeting. The AOR may cancel the daily
              check-in or substitute a technical or program specific meeting as a replacement. Daily check-ins are expected only on business days during normal business hours.

   

  		C.	Confirmed, critical programmatic concerns, issues or probable risks that are likely to impact project
              schedule/cost/performance: The Awardee will communicate and document all confirmed programmatic risks to the AOR within [**] of Awardee’s awareness. Awardee shall communicate via email or telephone.
              Following resolution, Awardee will provide all associated deviation reports and corrective and preventative action plans to the AOR within [**] of finalization.

   

  In addition, the Awardee will report to the government any activity or incident that is in violation of
      established security standards or indicates the loss or theft of government products within [**] of Awardee’s awareness of the activity or incident. Awardee will communicate via email, oral or written communication.

   

  		D.	Supply chain resiliency, including Awardee locations: Within [**] of award, the
              Awardee will provide the AOR with a supply chain resiliency plan. For each of the Awardee locations - including sub-agreement holders, the Awardee will provide address, point(s) of contact and a summary of work performed at the location.

   

  
     

    
      
 

  

   

  		E.	Quarterly Financial Status Report:

   

  The Awardee shall submit a Quarterly Financial Status Report no later than [**] after the end of each
      quarter of performance. The Government will have

  [**] to respond to the report with any comments and the Awardee will have an additional [**] to revise
      the deliverable or respond to those comments. Reports will cover work performed every three (3) months for the duration of the Period of Performance (PoP).

   

  For the industrial expansion effort, the Quarterly Financial Status Report shall include quarterly
      expenditure forecasts with both the quarterly planned accrual and the cumulative total. Expenditure forecast submissions shall include analysis of the cost drivers for Estimate to Complete changes, if any, from the previous projection. The Awardee
      shall provide all submissions in Excel format, including all formulas.

   

  ARTICLE 17:    Miscellaneous Clauses.

   

  A.           No Consent. Nothing in the terms of this Agreement constitutes
      express or implied Government authorization and consent for Awardee or its subawardee(s) to utilize, manufacture or practice inventions covered by United States or foreign patents in the performance of work under this Agreement.

   

  B.            Patent Infringement. Each Party will advise the other Party
      promptly and in reasonable written detail, of each claim or lawsuit of patent infringement based on the performance of this Agreement. When requested by either Party, all evidence and information in possession of the Party pertaining to such claim or
      lawsuit will be provided to the other at no cost to the requesting Party.

   

  C.            Limitation of Liability. In no event will either Party be liable
      to the other Party or any third party claiming through such Party for any indirect, incidental, consequential or punitive damages, or claims for lost profits, arising under or relating to this Agreement, whether based in contract, tort or otherwise,
      even if the other Party has been advised of the possibility of such damages.

   

  D.            Disclosure of Information. Subject to Article 10, the Awardee
      shall not release to anyone outside the Awardee’s organization any unclassified information, regardless of medium (e.g., film, tape, document), pertaining to any part of this Agreement or any program related to this Agreement, unless (i) the OTAO has
      given prior written approval or (ii) the information is otherwise in the public domain before the date of release. For purposes of this clause, Awardee’s Organization includes entities identified as Collaborators in

   

  E.             Force Majeure. Neither Party will be liable to the other Party
      for failure or delay in performing its obligations hereunder if such failure or delay arises from circumstances beyond the control and without the fault or negligence of the Party (a Force Majeure event). Examples of such circumstances are:
      authorized acts of the government in either its sovereign or contractual capacity, war, insurrection, freight embargos, fire, flood, or strikes. The Party asserting Force Majeure as an excuse must take reasonable steps to minimize delay or damages
      caused by unforeseeable events.

   

  
     

    
      
 

  

   

  F.             Severability. If any provision of this Agreement, or the
      application of any such provision to any person or set of circumstances, is determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to persons or circumstances
      other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by law.

   

  G.            Choice of Law. This Agreement and the resolution of disputes
      hereunder will be governed, construed, and interpreted by the statutes, regulations, and/or legal precedent applicable to the Government of the United States of America. Unless explicitly stated, the Parties do not intend that this Agreement be
      subject to the Federal Acquisition Regulation either directly or indirectly or by operation of law. When a specific FAR requirement is incorporated by reference in this Agreement, the text of the clause alone will apply without application or
      incorporation of other provisions of these regulations.

   

  H.            Order of Precedence. In the event of a conflict between the
      terms of this Agreement and the attachments incorporated herein, the conflict shall be resolved by giving precedence in descending order as follows: (i) the Articles of this Agreement, and the Appendices to the Agreement.

   

  ARTICLE 18:     PROHIBITION ON THE USE OF CERTAIN TELECOMMUNICATIONS AND VIDEO
      SURVEILLANCE SERVICES OR EQUIPMENT

   

  a) Definitions. As used in this clause—

   

  Backhaul means intermediate links between the core network, or backbone network, and the small
      subnetworks at the edge of the network (e.g., connecting cell phones/towers to the core telephone network). Backhaul can be wireless (e.g., microwave) or wired (e.g., fiber optic, coaxial cable, Ethernet).

   

  Covered foreign country means The People’s Republic of China.

   

  Covered telecommunications equipment or services means-

   

  		(1)	Telecommunications equipment produced by Huawei Technologies Company or ZTE Corporation (or any subsidiary or affiliate
            of such entities);

   

  		(2)	For the purpose of public safety, security of Government facilities, physical security surveillance of critical
            infrastructure, and other national security purposes, video surveillance and telecommunications equipment produced by Hytera Communications Corporation, Hangzhou Hikvision Digital Technology Company, or Dahua Technology Company (or any
            subsidiary or affiliate of such entities);

   

  
     

    
      
 

  

   

  		(3)	Telecommunications or video surveillance services provided by such entities or using such equipment; or

   

  		(4)	Telecommunications or video surveillance equipment or services produced or provided by an entity that the Secretary of
            Defense, in consultation with the Director of National Intelligence or the Director of the Federal Bureau of Investigation, reasonably believes to be an entity owned or controlled by, or otherwise connected to, the government of a covered
            foreign country.

   

  Critical technology means-

   

  		(1)	Defense articles or defense services included on the United States Munitions List set forth in the International Traffic
            in Arms Regulations under subchapter M of chapter I of title 22, Code of Federal Regulations;

   

  		(2)	Items included on the Commerce Control List set forth in Supplement No. 1 to part 774 of the Export Administration
            Regulations under subchapter C of chapter VII of title 15, Code of Federal Regulations, and controlled-

   

  		(i)	Pursuant to multilateral regimes, including for reasons relating to national security, chemical and biological weapons
            proliferation, nuclear nonproliferation, or missile technology; or

   

  		(ii)	For reasons relating to regional stability or surreptitious listening;

   

  		(3)	Specially designed and prepared nuclear equipment, parts and components, materials, software, and technology covered by
            part 810 of title 10, Code of Federal Regulations (relating to assistance to foreign atomic energy activities);

   

  		(4)	Nuclear facilities, equipment, and material covered by part 110 of title 10, Code of Federal Regulations (relating to
            export and import of nuclear equipment and material);

   

  		(5)	Select agents and toxins covered by part 331 of title 7, Code of Federal Regulations, part 121 of title 9 of such Code,
            or part 73 of title 42 of such Code; or

   

  		(6)	Emerging and foundational technologies controlled pursuant to section 1758 of the Export Control Reform Act of 2018 (50
            U.S.C. 4817).

   

  Interconnection arrangements means arrangements governing the physical connection of two or more
      networks to allow the use of another’s network to hand off traffic where it is ultimately delivered (e.g., connection of a customer of telephone provider A to a customer of telephone company B) or sharing data and other information resources.

   

  Reasonable inquiry means an inquiry designed to uncover any information in the entity’s
      possession about the identity of the producer or provider of covered telecommunications equipment or services used by the entity that excludes the need to include an internal or third-party audit.

   

  
     

    
      
 

  

   

  Roaming means cellular communications services (e.g., voice, video, data) received from
      a visited network when unable to connect to the facilities of the home network either because signal coverage is too weak or because traffic is too high.

   

  Substantial or essential component means any component necessary for the proper function or
      performance of a piece of equipment, system, or service.

   

  		(b)	Prohibition.

   

  (1) Section 889(a)(1)(A) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019
      (Pub. L. 115-232) prohibits the head of an executive agency on or after August 13, 2019, from procuring or obtaining, or extending or renewing a contract to procure or obtain, any equipment, system, or service that uses covered telecommunications
      equipment or services as a substantial or essential component of any system, or as critical technology as part of any system. The Contractor is prohibited from providing to the Government any equipment, system, or service that uses covered
      telecommunications equipment or services as a substantial or essential component of any system, or as critical technology as part of any system, unless an exception at paragraph (c) of this clause applies or the covered telecommunication equipment or
      services are covered by a waiver described in FAR 4.2104.

   

  (2) Section 889(a)(1)(B) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019
      (Pub. L. 115-232) prohibits the head of an executive agency on or after August 13, 2020, from entering into a contract or agreement, or extending or renewing a contract or agreement, with an entity that uses any equipment, system, or service that
      uses covered telecommunications equipment or services as a substantial or essential component of any system, or as critical technology as part of any system, unless an exception at paragraph (c) of this clause applies or the covered telecommunication
      equipment or services are covered by a waiver described in FAR 4.2104. This prohibition applies to the use of covered telecommunications equipment or services, regardless of whether that use is in performance of work under a Federal contract
      or agreement.

   

  		(c)	Exceptions. This clause does not prohibit contractors from providing—

   

  (1)  A service that connects to the facilities of a third-party, such as backhaul, roaming, or
      interconnection arrangements; or

   

  (2)   Telecommunications equipment that cannot route or redirect user data traffic or permit
      visibility into any user data or packets that such equipment transmits or otherwise handles.

   

  		(d)	Reporting requirement

   

  (1)   In the event the Contractor identifies covered telecommunications equipment or services used as
      a substantial or essential component of any system, or as critical technology as part of any system, during contract or agreement performance, or the Contractor is notified of such by a subcontractor at any tier or by any other source, the Contractor
      shall report the information in paragraph (d)(2) of this clause to the Agreements Officer, unless elsewhere in this contract or agreement are established procedures for reporting the information; in the case of the Department of Defense, the
      Contractor shall report to the website at https://dibnet.dod.mil.

   

  
     

    
      
 

  

   

  (2)   The Contractor shall report the following information pursuant to paragraph (d)(1) of this
      clause

   

  (i)       Within [**] from the date of such identification or notification: the contract number; the
      order number(s), if applicable; supplier name; supplier unique entity identifier (if known); supplier Commercial and Government Entity (CAGE) code (if known); brand; model number (original equipment manufacturer number, manufacturer part number, or
      wholesaler number); item description; and any readily available information about mitigation actions undertaken or recommended.

   

  (ii)       Within [**] of submitting the information in paragraph (d)(2)(i) of this clause: any further
      available information about mitigation actions undertaken or recommended. In addition, the Contractor shall describe the efforts it undertook to prevent use or submission of covered telecommunications equipment or services, and any additional efforts
      that will be incorporated to prevent future use or submission of covered telecommunications equipment or services.

   

  (e)          Subcontracts. The Contractor shall insert the substance of this clause, including this
      paragraph (e) and excluding paragraph (b)(2), in all subcontracts, subagreements and other contractual instruments, including subcontracts for the acquisition of commercial items.

   

  
     

    
      
 

  

   

  Appendix A Statement of Work

   

  Statement of Work (SOW): Point-of-Care (POC) Tests and Diagnostics

   

  C.1. General Objectives.

   

  The U.S. Government (USG) requires additional POC diagnostic test capacity, as the level of demand for diagnostic
      resources during this COVID-19 Pandemic is unprecedented. There is a need to secure additional POC diagnostics to test the US population in response to the Pandemic. The Government seeks to expand the production capacity for Monitoring Systems and
      COVID-19 Test Cartridges. The end deliverable of this effort is to provide the capacity to manufacture 100,000 cartridges per day.

   

  As part of this effort, there shall result in an increase to its industrial base manufacturing capability for
      COVID-19 Test Cartridges within the U.S., to include critical supply chain providers to 100,000 cartridges per day. The Awardee shall also onshore its cartridge and reader subcomponents manufacturing to the maximum extent possible, to further reduce
      supply chain risk. The Awardee shall also develop a distribution process and increase shipping capability in order to ship all materials directly to the customer location.

   

  C.2. Prototype Delivery.

   

  C.2.2. The Awardee shall increase its industrial base manufacturing capability to manufacture 100,000 cartridges
      per day.

   

  C.2.2.1. The Awardee shall increase the manufacturing capability for the COVID-19 Test Cartridges to
      100,000 cartridges per day.

   

  C.2.2.2. The Awardee shall onshore its cartridge and reader subcomponents manufacturing.

   

  C.2.2.3. The Awardee shall develop and expand its distribution process in order to ship all materials
      directly to the customer location within the United States and its Territories.

   

  C.3. Demonstration of Prototype Delivery.

   

  C.3.1. The Awardee shall deliver 6 million COVID-19 Test Cartridge Packs.

   

  C.3.2. The Awardee shall deliver 30,000 Health Monitoring Systems.

   

  C.3.3. The Awardee shall deliver 60,000 COVID-19 External Control Swabs Packs.

   

  C.3.4. The Awardee shall ship all deliverables to locations (TBD) within the United States.

   

  C.3.5. The Awardee shall ensure appropriate quality assurance certification is supplied with each shipment.

   

  
     

    
      
 

  

   

  C.4. Overall Management Objectives.

   

  C.4.1. The Awardee shall be responsible for overall management and oversight of the work necessary to achieve the
      objectives of this contract. The Contractor shall provide the overall management, integration, and coordination of all contractual activities, including a technical and administrative infrastructure to ensure the efficient planning, initiation,
      implementation, and direction of all contractual activities.

   

  The Contractor shall establish project milestones for each manufacturing capability/capacity for which expansion
      is planned. The Awardee shall provide incremental progress against each milestone to the USG in accordance with established deliverables (see C.6 below). The Awardee shall report to the USG any changes or deviations planned or incurred by the
      Contractor in pursuing the objectives of this contract. While primary responsibility for management and execution of the effort resides with the Awardee, the USG shall have input to the milestone review process and any changes to the objectives of
      the agreement.

   

  C.5. Risk Management Objectives.

   

  The Awardee shall identify all anticipated project risks categorized as moderate or high and report them to the
      USG in accordance with reporting requirements (see C.6 below). The Awardee shall manage all project risks using its in- house risk management capabilities, and report to the USG changes to all identified risks as they occur/arise. The USG shall be
      permitted to participate in the risk management and mitigation processes associated with this project.

   

  C.6. Status Reporting.

   

  C.6.1. Monthly Progress Reports. The Awardee shall submit monthly progress reports no later than the [**] of the
      month. Awardee format acceptable. Electronic submission acceptable in MS Office or PDF format. Financial information shall be MS Excel format. Monthly reports shall NOT be marked proprietary, and shall have Distribution Statement C (US Government and
      their contractors). Each monthly report shall, at a minimum, contain the following:

  		●	Summary of monthly progress for each of the Awardee’s facilities/capabilities associated with this effort.

  		●	Summary of progress towards established milestones for each facility/capability.

  		●	Identification of any milestone that is slipping or missed, and discussion of path forward to bring milestone back to
            schedule, and impact on other milestones.

  		●	Summary of risks, discussion of potential impacts and efforts to mitigate.

  		●	Summary of overall schedule and changes from previous month.

  		●	Status updates from Manufacturing plan

  		●	Status updates from Distribution plan

  		●	Report any customer complaints

  		●	Report any known deficiencies of the materials and/or products

  		●	Financial summary of Awardee costs incurred by month to date, invoices submitted, and Government payments made.

   

  C.6.2. Weekly Progress Meetings. Scheduled on a weekly basis, virtual format (either telephone or
      videoconference), between the Contractor and the Government. Duration: [**] max. Review of previous weeks activities. Informative in nature to keep the USG apprised of project progress and to discuss issues that may require joint resolution, such as
      milestone changes, political impacts on objectives, schedule, funding and deliverables. Meeting minutes provided by the Awardee delivered to the USG within [**] of the meeting.

   

  
     

    
      
 

  

   

  C.6.3. Quarterly In Process Reviews. Scheduled as needed, generally not more frequently than quarterly, virtual
      format (either telephone or videoconference). Duration: [**] max. Review of previous quarter’s activities. Informative in nature to keep the USG apprised of project progress and to discuss issues that may require joint resolution, such as milestone
      changes, political impacts on objectives, schedule, funding. An agenda for the meeting provided by the Awardee [**] prior to the scheduled meeting. Meeting minutes provided by the Awardee delivered to the USG within [**] of the meeting.

   

  C.6.4. Final Report. Final Report shall NOT be marked proprietary, and shall have Distribution Statement C.
      Contractor format acceptable. Electronic submission acceptable in MS Office or PDF format. Financial information shall be MS Excel format. Final report summarizing stated objectives and the progress that was achieved in meeting those objectives;
      summary of risks incurred, impacts and mitigation; quantitative discussion of production throughput improvements achieved; financial summary of project; schedule summary for project, comparing original schedule to final schedule; recommendations for
      path forward as applicable. Final Report due [**] after the last scheduled delivery for prototype demonstration.

   

  C.6.5. Manufacturing Plan. The Awardee shall provide a detailed plan of action (contractor format acceptable) to
      increase cartridge-manufacturing capability to meet the government’s delivery schedule (i.e. ramp up to 100K cartridges per day) and associated on-shoring component manufacturing within [**] of contract award.

   

  The Awardee’s plan of action shall at a minimum, include the following:

   

  		a	Timeline, materials required and strategy to set up and begin V2.0 manufacturing lines to manufacture the cartridges;

  		b	Timeline, materials required and strategy to upgrade the bioproduction capability to manufacture sufficient cartridge
            reagents;

   

  		c	Timeline, materials required and strategy to onshore manufacturing of reagents and cartridge subcomponents;

  		d	Information on the US based manufacturing organization to replace existing organization;

  		e	Current GMP manufacturing status and plan to achieve GMP manufacturing, if not currently GMP;

  		f	Quality Assurance plan and Acceptance metrics;

  		g	Plan to comply with FDA EUA Letter of Authorization.

   

  C.6.6. Distribution Plan. The Awardee shall provide a detailed distribution plan for how all Test
      Cartridge Packs, Monitoring Systems and External Control Swabs Packs will be shipped and delivered to required delivery locations within the United States and its Territories within [**] of contract award.

   

  
     

    
      
 

  

   

  The Awardee’s distribution plan shall at a minimum, include the following: a Current distribution
      processes; b Timeline and strategy to increase distribution process and shipping to handle the increase in number and volume of shipments.

   

  C.6.7 Quality Management Plan. The Awardee shall provide (contractor format acceptable) within [**] of
      contract award, a quality management plan for manufacturing efforts that conform to ISO 13485 standards as well as the Quality System Regulations at 21 CFR Part 820 which may include, but is not limited to, the quality policy and objectives,
      management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes. The framework is normally divided into
      infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.

   

  Appendix B

      Project Schedule/Milestone Payment Schedule

   

  The Government shall pay the Awardee, upon the submission of proper invoices or vouchers, the prices stipulated
      in this Agreement for supplies delivered and accepted or services rendered and accepted, less any deductions provided in this Agreement.

   

  For the industrial expansion, expenditures shall be submitted based on the awarded budget. Federal funds are to
      be used only for work that a reasonable and prudent person would incur in carrying out the prototype project. An invoice will be submitted through Wide Area Work Flow (WAWF) in accordance with agreement requirements. Final payment of the Agreement
      shall be determined upon mutual agreement and settlement of any outstanding deliverables.

   

  The Awardee shall proceed with the performance in accordance with the terms and conditions of this Agreement and
      its Appendices. However, the Government may require the Awardee to cease performance at any time prior to the commencement of any milestone or task. Such notice to cease performance must be from the OTAO and be in writing, of which email is an
      acceptable form.

   

  The Parties acknowledge that the nature of this Prototype Project requires flexibility and the ability to react
      to changing circumstances. Although the Statement of Work sets the scope for activities the Government may require under this Agreement, it is not intended to, and does not, prescribe with specificity each task that Awardee will perform. Instead, the
      Government shall direct Awardee to perform specific tasks under the framework established in Articles 3 and 8 of the Agreement, with Government-approved tasks, funding, and deadlines. Awardee shall not perform any tasks that have not been explicitly
      authorized by the Government.

   

  Awardee will be responsible for submission of SOW’s, quotes, and proposals for price, performance, and schedule
      for those efforts not already identified, priced or otherwise negotiated. Government approval will be required prior to commencing work.

   

  
     

    
      
 

  

   

  Appendix C

      Key Personnel

   

  1.       Awardee’s Organization and Key Personnel.

   

  a.       The Awardee’s organization shall be established with authority to effectively accomplish the objectives
      of the Statement of Work. This organization shall become effective upon award of the Agreement and its integrity shall be maintained for the duration of the effort.

   

  b.       The key personnel listed below are considered to be critical to the successful performance of this
      Agreement. Prior to replacing these key personnel, the Awardee shall obtain the written consent of the OTAO. In order to obtain such consent, the Awardee shall provide advance notice of the proposed changes and shall demonstrate that the
      qualifications of the proposed substitute personnel are generally equivalent to or better than the qualifications of the personnel being replaced.

   

  c.       Prior to permanently removing any of the specified individuals to other contracts, the Awardee shall
      provide the OTAO not less than [**] advance notice and shall submit justification (including proposed substitutions) in sufficient detail to permit evaluation of the impact on the program. No reassignment shall be made by the Awardee without written
      consent of the OTAO. The “Key Personnel” list presented in Table 2 below may be amended from time to time during the course of the Agreement to either add or delete personnel, as appropriate.

   

  Table 2: Key Personnel Summary

   

  
     

    
      
 

  

   

  Appendix D

      Government Property

   

  Government Property: “Government Property” means any property (i) furnished by the Government and
      facilitating performance of this Agreement, (ii) acquired by the Awardee under cost reimbursement terms of this Agreement, or (iii) acquired by the Awardee under fixed price terms of this Agreement (FP-GP) if specifically identified in this
      Government Property Appendix. Except for commercial off the shelf software and licenses thereto, Government Property does not include intellectual property and software. The Government owns and holds title to all Government Property.

   

  The Government shall deliver to the Awardee any Government Property required to be furnished as described in this
      Agreement together with related data and information needed for its intended use. The delivery and/or performance dates specified in this Agreement are based upon the expectation that the Government-furnished property will be suitable for performance
      and will be delivered to the Awardee by the dates stated in the Agreement. If not so suitable, the Awardee shall give timely written request to the OTAO who will advise the Awardee on a course of action to remedy the problem.

   

  FPGP includes: [Mark N/A if none]:

   

  
    N/A

     

  

   

  The Awardee shall have, initiate and maintain a system of internal controls to manage, control, use, preserve, protect, repair,
      account for and maintain Government Property in its possession and shall initiate and maintain the processes, systems, procedures, records required control and maintain accountability of Government Property.

   

  The Awardee shall include this clause in all subcontracts under which Government Property comes into the
      possession of any subawardee. Unless otherwise provided for in this Agreement or approved by the OTAO, the Awardee shall not: (i) use Government Property for any purpose other than to fulfill the requirements of this Agreement, or (ii) alter the
      Government Property.

   

  The Awardee shall establish and implement property management plans, systems, and procedures regarding its
      acquisition of Government Property, its receipt of Government Property, in addition to, the status, dates furnished or acquired, identification, quantity, cost, marking, date placed in service, location, inventory and disposition of Government
      Property, to include a reporting process for all discrepancies, loss of Government Property, physical inventory results, audits and self-assessments, corrective actions, and other property related reports as directed by the OTAO.

   

  Upon conclusion or termination of the Agreement, the Awardee shall submit a request in writing to the OTAO, for
      disposition/disposal instructions and shall store Government Property not to exceed [**] pending receipt of such instructions. Storage shall be at no additional cost to the Government unless otherwise noted in the Agreement. The Government, upon
      written notice to the Awardee, may abandon any Government Property in place, at which time all obligations of the Government regarding such Government Property shall cease.

   

  
     

    
      
 

  

   

  Awardee Liability for Government Property. “Loss of Government Property” means the loss, damage or
      destruction to Government Property reducing the Government’s expected economic benefits of the property and includes loss of accountability but does not include planned and purposeful destructive testing, obsolescence, reasonable wear and tear or
      manufacturing defects. THE AWARDEE SHALL BE LIABLE FOR LOSS OF GOVERNMENT PROPERTY IN AWARDEE’S POSSESSION, EXCEPT WHEN ANY ONE OF THE FOLLOWING APPLIES: (I) OTAO GRANTS RELIEF OF RESPONSIBILITY AND LIABILITY FOR LOSS OF THE PARTICULAR GOVERNMENT
      PROPERTY; (II) GOVERNMENT PROPERTY IS DELIVERED OR SHIPPED UNDER THE GOVERNMENT’S INSTRUCTIONS AND SHIPPERS; OR (III) GOVERNMENT PROPERTY IS DISPOSED OF IN ACCORDANCE WITH THE GOVERNMENT’S DIRECTIONS.

   

  
     

    
      
 

  

   

  Section E - Inspection and Acceptance

   

  INSPECTION AND ACCEPTANCE TERMS

   

  Supplies/services will be inspected/accepted at:

   

  	CLIN	INSPECT AT	INSPECT BY	ACCEPT AT	ACCEPT BY
	0001	N/A	N/A	N/A	Government
	0002	N/A	N/A	N/A	Government
	0003	N/A	N/A	N/A	Government
	0004	N/A	N/A	N/A	Government

   

  
     

    
      
 

  

   

  Section F - Deliveries or Performance

   

  DELIVERY INFORMATION

   

  	CLIN	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC / CAGE
	0001	08-APR-2021	1	
          JPM MEDICAL

          JPM CBRN MEDICAL

          1564 FREEDMAN DRIVE

          FORT DETRICK, MD MD 21702 240-675-3192

          FOB: Origin (Shipping Point)

        	W56XNH
	0002	11-MAR-2021	6,000,000	(SAME AS PREVIOUS LOCATION) FOB: Origin (Shipping Point)	W56XNH
	0003	11-MAR-2021	30,000	(SAME AS PREVIOUS LOCATION) FOB: Origin (Shipping Point)	W56XNH
	0004	11-MAR-2021	60,000	(SAME AS PREVIOUS LOCATION) FOB: Origin (Shipping Point)	W56XNH

   

  
     

    
      
 

  

   

  Section G - Contract Administration Data

   

  ACCOUNTING AND APPROPRIATION DATA

   

  AA: 0212020202120400000664643255 S.0074658.5.22 6100.9000021001

  COST CODE: A5XAH

  AMOUNT: $480,916,636.62

   

  	
          ACRN

        	
          CLIN/SLIN

        	
          CIN

        	
          AMOUNT

        
	 	 	 	 
	AA	0001	GFEBS001156060100001	$184,576,636.62
	 	0002	GFEBS001156060100002	[**]
	 	0003	GFEBS001156060100003	[**]
	 	0004	GFEBS001156060100004	[**]

   

  
     

    
      
 

  

   

   

   

   

  
     

    
      
 

  

   

  Contract Modification Continuation Page

  Page 2 of 2

  Contract W911NF2190001

  Modification Number: A00002

  Modification Effective Date: 28 DEC 2020

   

  PURPOSE OF MODIFICATION:

  This Unilateral Other Administrative Action Modification is issued pursuant to: FAR 42.302(a).

   

  The purpose of this no-cost unilateral modification is to incorporate the approved Health Resources Priority and
      Allocations System (HRPAS) to aid in the procurement of supplies in support of Operation Warp Speed (OWS). The HRPAS Rating memo dated 22 December 2020 is attached herein.

   

  Ship To location is changed as follows: from: W56XNH to: SW3100, [**], and SW3200, [**] for CLINS 0002, 0003, and
      0004. Delivery quantities stated on Table 2B to each location are to be determined in advance of shipment by AOR [**].

   

  CLOSING REMARKS:

  The USD Cost Amount is USD 0.00.

  The USD Fee Amount is USD 0.00.

  The total funds obligated to this Contract equal USD 480,916,636.62.

  The USD Total Contract Amount is USD 480,916,636.62.

   

  As a result of this modification, the total obligated amount of this contract is unchanged.

      The total contract amount of this contract is unchanged.

   

  List of Attachments

   

  CUE_HRPAS_Signed_Memo_122220.pdf   HRPAS Signed Memo 122220

      Ship_To_Locations_email_122820.pdf         ShipTo Locations email

   

  Except as provided by this contract modification, all terms and conditions of this contract remain unchanged
        and in full force and effect.

   

  
     

    
      
 

  

   

   

  

   

   

  
     

    
      
 

  

   

  Contract Modification Continuation Page

  Page 2 of 2

  Contract W911NF2190001

  Modification Number: A00003

  Modification Effective Date: 03 FEB 2021

   

  PURPOSE OF MODIFICATION:

  This Bilateral Other Administrative Action Modification is issued pursuant to:

      FAR 42.302(a) The purpose of this bilateral modification is to make administrative revisions to this OTA as follows:

   

  1.       Remove Articles # 16 D AND 16 E as redundant or no longer required on this OTA.

   

  Article 16, D, Supply chain resiliency plan

  Article 16, E Quarterly Financial Status Report

   

  2.       This is a DO-HR rated order for the purpose of emergency preparedness and the
      Contractor shall follow all the provisions of the Health Resources Priorities and Allocations System regulation (45 CFR Part 101). If the contractor needs to utilize industrial resources to fulfill this rated order for a health resource, it is
      authorized pursuant to 45 CFR §101.35(b) to place the same priority rating and program identification symbol for health resources on its orders for industrial resources with its suppliers. The HRPAS Rating Memo dated 22 December 2020 authorized the
      rating of DO-HR to aid in the procurement of supplies in support of Operation Warp Speed (OWS). The priority rating must be included on each successive order placed to obtain items or services needed to fill a customer's rated order. This continues
      from contractor to subcontractor to supplier throughout the entire procurement chain.”

   

  CLOSING REMARKS:

   

  The USD Cost Amount is USD 0.00.

  The USD Fee Amount is USD 0.00.

  The total funds obligated to this Contract equal USD 480,916,636.62.

  The USD Total Contract Amount is USD 480,916,636.62.

   

  As a result of this modification, the total obligated amount of this contract is unchanged.

  The total contract amount of this contract is unchanged.

  Except as provided by this contract modification, all terms and conditions of this contract remain unchanged
        and in full force and effect.

   

  
     

    
      
 

  

   

   

   

  
     

    
      
 

  

   

  Contract Modification Continuation Page

  Page 2 of 4

  Contract W911NF2190001

  Modification Number: A00003

  Modification Effective Date: 03 MAR 2021

   

  PURPOSE OF MODIFICATION:

  This Bilateral Other Administrative Action Modification is issued pursuant to:

      In accordance with the coordinated agreement to benefit both the Government and the Awardee to expand Cue's shipping and distribution capability, this modification is to effect the following changes:

   

  ARTICLE 15:

   

  1.) From: “A. Delivery and Acceptance. Awardee shall notify the AO and AOR at least [**] prior to initial
      delivery of first shipment of test kits. Exceptions are permitted if approved by the AO. Upon notification, the AOR will instruct the Awardee to deliver kits to either up to [**] centralized Government designated distribution sites within the
      continental United States or up to [**] additional specific individual final destinations within the continental United States. Upon delivery of product, notification of delivery quantities shall be made to the AOR.”

   

  To: “A. Delivery and Acceptance. Awardee shall notify the AO and AOR at least [**] prior to initial
      delivery of first shipment of test kits. Exceptions are permitted if approved by the AO. Upon notification, the AOR will instruct the Awardee to deliver kits to up to [**] centralized Government-designated distribution sites within the continental
      United States and up to [**] additional specific individual final destinations within the continental United States. The AOR and Awardee shall agree on the locations prior to each delivery. For locations without a CAGE code or DODAAC, the Awardee
      shall Ship In Place and use the Awardee's own CAGE code to invoice in WAWF. Upon acceptance by DCMA on site, the Awardee shall fill out an 1149 form to verify delivery of the product to each location for all Ship In Place deliveries. For locations
      with a valid CAGE code or DODAAC, the Awardee shall Ship to Destination with the location's CAGE code or DODAAC to invoice in WAWF. Upon delivery of product, notification of delivery quantities shall be made to the AOR.”

   

  2.) From: “The Government shall accept product that conforms to contract requirements based on Certificates of
      Analysis and certificate(s) of cGMP conformity provided by Awardee and review of temperature monitoring data.”

   

  To: “The Government shall accept product that conforms to agreement requirements based on Certificates of Analysis
      and/or certificate(s) of conformity provided by Awardee and review of temperature monitoring data .”

   

  ARTICLE 1 B.1

   

  3.) From: “The prototype project under this Agreement is the demonstration by Awardee of the rapid, large scale
      supply and logistics capability to manufacture and deliver to the Government within 5 months of the effective date of this Agreement 6 million Cue COVID-19 Assay Cartridges, 60,000 COVID-19 Control Swab Packs, and 30,000 Monitoring Systems by
      achieving a sustained average per day production rate of at least 100,000 EUA or 510(k) cleared Cue COVID-19 Assay Cartridges over the last 7 days of the 5 month delivery period.”

   

  To: “The prototype project under this Agreement is the demonstration by Awardee of the rapid, large scale supply
      and logistics capability to manufacture and deliver to the Government within 12 months of the effective date of this Agreement at least 6 million Cue COVID-19 Assay Cartridges, 60,000 COVID-19 Control Swab Packs, and 30,000 Monitoring Systems by
      achieving a sustained average per day production rate of approximately 100,000 EUA or 510(k) cleared Cue COVID-19 Assay Cartridges over a consecutive 7 day period during the 12 month delivery period.”

   

  4.) From: “The prototype project will be successfully completed when Awardee has achieved a sustained average per
      day production rate of at least 100,000 EUA or 510(k) cleared COVID-19 Assay Cartridges over a 7 day period, and has delivered a total of 6 million Cue COVID-19 Assay Cartridges, 30,000 monitoring systems, and 60,000 control swab packs.”

   

  
     

    
      
 

  

   

  Contract Modification Continuation Page

  Page 3 of 4

  Contract W911NF2190001

  Modification Number: A00003

  Modification Effective Date: 03 MAR 2021 

   

  To: “The prototype project will be successfully completed when Awardee has achieved a sustained average per day
      production rate of approximately 100,000 EUA or 510(k) cleared COVID-19 Assay Cartridges over a consecutive 7-day period during the 12 month delivery period, and has delivered a total of at least 6 million Cue COVID-19 Assay Cartridges, 30,000
      monitoring systems, and 60,000 control swab packs.”

   

  Article 1. B.7

   

  5.) From: “Deliverables: Deliverables under this Agreement are listed in Table 1.

      Variances: Awardee shall promptly notify the Government of any anticipated shortage in quantity or deviation from any delivery date specified herein. The Government and the Awardee shall cooperate in good faith to adjust
        Table 1 to reflect reasonable variations in the delivery schedule, provided that the total scheduled quantities are delivered and Awardee demonstrates a production capacity of 100,000 units per day within not more than [**] after award.”

   

  To: “Deliverables: Deliverables under this Agreement are listed in Table 1.

      Variances: Awardee shall promptly notify the Government of any anticipated shortage in quantity or deviation from any delivery date specified herein. The Government and the Awardee shall cooperate in good faith to adjust
        Table 1 to reflect reasonable variations in the delivery schedule, provided that the total scheduled quantities are delivered and Awardee demonstrates a sustained average per day production rate over a consecutive 7-day period of approximately
        100,000 EUA or 510(k) cleared units within not more than 12 months from the effective date of this agreement.”

   

  Article 2.A.

   

  6.) From: “The Term of this Agreement commences upon the Effective Date and extends through final payment. This
      Agreement is anticipated to end 5 months after the Effective Date, subject to mutually agreed extensions pursuant to paragraph 2.D to facilitate the completion of the project(s).”

   

  To: “The Term of this Agreement commences upon the Effective Date and extends through final payment. This
      Agreement is anticipated to end 12 months after the Effective Date, subject to mutually agreed extensions pursuant to paragraph 2.E to facilitate the completion of the project(s).” The period of performance is hereby extended to October 12, 2021.

   

  
     

    
      
 

  

   

  Contract Modification Continuation Page

  Page 4 of 4

  Contract W911NF2190001

  Modification Number: A00003

  Modification Effective Date: 03 MAR 2021

   

  CLOSING REMARKS:

  The USD Cost Amount is USD 0.00.

  The USD Fee Amount is USD 0.00.

  The total funds obligated to this Contract equal USD 480,916,636.62.

  The USD Total Contract Amount is USD 480,916,636.62.

   

  As a result of this modification, the total obligated amount of this contract is unchanged.

  The total contract amount of this contract is unchanged.

  Except as provided by this contract modification, all terms and conditions of this contract remain unchanged
        and in full force and effect.

  
    
      

  

  
    	
            DATE:

          	
            April 19, 2021

             

            

          
	
            TO:

          	
            Vonetta Goodson McNeal 

            

            Agreements Officer 

            

            Division Chief, Army Contracting Command- Aberdeen Proving Ground

             

            

          
	
            FROM:

          	
            Michael F. Iademarco, MD, MPH 

            

            RADM, U.S. Public Health Service 

            

            U.S. Department of Health and Human Services

             

            

          
	
            SUBJECT:

          	
            Cue Health, Inc. Waiver Request Approval

          

    

    

    
      According to the Cue Health, Inc. (Cue) Other Transaction Authority for Prototype Agreement (Agreement No. W911NF-21-9-0001) dated October
        13, 2020, Article 1, Scope of the Agreement, para.1, the U.S. Government will be the exclusive purchaser of the entire production of the Awardee’s COVID-19 Test until the prototype project has been successfully completed, provided that: (1) Awardee
        may honor contractual commitments executed before the effective date of the Agreement; (2) Awardee may request a waiver from the Government to respond to other than U.S. Federal Government urgent diagnostic testing requirements; and (3) Awardee may
        use a reasonable number of tests for internal workforce testing and diagnostic purposes and for marketing, demonstration and evaluation and business development.

      

      

      Pursuant to clause (2) above, Cue submitted a request for a waiver to fulfill commercial orders as follows:

      

      

    

    	

          	1.	
            Awardee may distribute commercially to recipients outside of the U.S. Federal Government up to one-half (50%) of the entire production of the Awardee’s COVID-19 Test, measured monthly in arrears on a calendar-month
              basis.

          

    

    

    	

          	2.	
            This waiver shall be effective as of May 1, 2021, applicable to the Awardee’s production of COVID-19 Tests during April 2021, and shall remain in effect for the duration of the Agreement, except as modified pursuant
              to paragraph 3 below.

          

    

    

    	

          	3.	
            The Government may modify this waiver to reasonably accommodate changes in Government requirements, by written notice to Awardee specifying the increased or decreased percentage of the Awardee’s COVID-19 Test
              production that may be distributed to non-U.S. Federal Government recipients and the effective date of the modification, which shall be no less than fourteen (14) days after Awardee’s receipt of such notice.

          

    

    

    
      As the requirements owner for the Cue OTA, I approve Cue’s waiver request to fulfill commercial orders as submitted.

    

    

    

    	
            /s/ Michael F. Iademarco

          	 	
            4/19/2021

          
	
            Michael F. Iademarco, MD, MPH

          	 	
            Date

          
	
            RADM, USPHS

          	 	 

  

  
    
      

  

  
    

    

    

    	
            DATE:

          	
            December 7, 2020

          
	 	 
	
            TO:

          	
            Vonetta Goodson McNeal

            Agreements Officer

            Division Chief, Army Contracting Command- Aberdeen Proving Ground

          
	 	 
	
            FROM:

          	
            Brett P. Giroir, M.D.

            ADM, U.S. Public Health Service

            U.S. Department of Health and Human Services, Assistant Secretary for Health

            U.S. Representative, Executive Board, WHO

          
	 	 
	
            SUBJECT:

          	
            Cue Health, Inc. Waiver Request Approval

          

    

    

    According to the Cue Health, Inc. (Cue) Other Transaction Authority (OTA) agreement number W911NF2190001, Article 1: Scope of the Agreement, 1. Prototype
      Project, the U.S. Government will be the exclusive purchaser of the entire production of the Awardee’s COVID-19 Test until the prototype project has been successfully completed, unless the Awardee requests a waiver to respond to other than the U.S.
      Government urgent diagnostic testing requirements.

    

    

    As the requirements owner for the Cue OTA, I approve Cue’s waiver requests to fulfill commercial orders as submitted:

    

    

    November 30, 2020: [**], for [**] Cue COVID-19 Test Cartridges and [**] Cue Health Monitoring systems.

    

    

    December 1, 2020: [**], for [**] Cue COVID-19 Test Cartridges and [**] Cue Health Monitoring systems.

    

    

    	
            
              

            

          	 	
            12/7/2020

          	 
	
            Brett P. Giroir, M.D.

            ADM, USPHS

          	 	
            Date

          	 

    

    

    

    

    

    

    

    

    [Type here]

    

    

    

    
      
        

    

    
      

      
        
          

      

      

      

      Page 2 of 3

        Contract: W911NF2190001

        Modification Number: A00005

        Modification Effective Date: 08 APR 2021

       
      

         

       
      PURPOSE OF MODIFICATION:

       
      

         

       
      This Bilateral Other Administrative Action Modification is issued pursuant to:

       
      FAR 42.302(c) The purpose of this modification is to affect the following changes:

       
      

         

       
      CLIN 0002

       
      From: COVID-19 TEST CARTRIDGES AS SPECIFIED IN AWARD NARRATIVE

       
      To: COVID-19 Test Cartridges

       
      

         

       
      CLIN 0003

       
      From: MONITORING SYSTEMS AS SPECIFIED IN AWARD NARRATIVE

       
      To: Health Monitoring Systems

       
      

         

       
      CLIN 0004

       
      From: SWAB PACKS AS SPECIFIED IN AWARD NARRATIVE

       
      To: COVID-19 External Control Swab Packs

       
      

         

       
      ARTICLE 15: INSPECTION AND ACCEPTANCE

       
      E. Risk of Loss Due to Expiry

       
      From: Both parties acknowledge that risk of loss due to expiry is retained by the Government for all product accepted under this Agreement. In order to
        mitigate this risk, the Awardee will make kits available for delivery to VMI or Government distribution sites within [**] of the date of manufacture. Provided this condition is met, the Awardee will have no obligation to replace product that has
        been accepted by the Government and expires prior to use.

       
      

         

       
      To: Both parties acknowledge that risk of loss due to expiry is retained by the Government for all product accepted under this Agreement. In order to mitigate
        this risk, the Awardee will make COVID-19 Test Cartridges available for delivery to VMI, Government distribution sites, or individual final destinations within [**] of the date of manufacture. The Awardee will make COVID-19 External Control Swab
        Packs available for delivery to VMI, Government distribution sites or individual final destinations within [**] of the date of manufacture. Provided this condition is met, the Awardee will have no obligation to replace product that has been
        accepted by the Government and expires prior to use.

       
      

         

       
      

         

       
      

         

       
      FAR 42.302(c) The purpose of this bilateral modification is to make administrative revisions to this OTA as follows:

       
      

         

       
      SUMMARY OF CHANGES:

       
      

         

       
      On Line Item 0002, the Line Item Description is changed from null to COVID-19 Test Cartridges. On Line Item 0002, the Noun is changed from TEST CARTRI to
        COVID-19 TE.

       
      
        
          

      

      

         

       
      Page 3 of 3

        Contract: W911NF2190001

        Modification Number: A00005

        Modification Effective Date: 08 APR 2021

       
      

         

       
      SUPPLIES OR SERVICES:

       
      

         

       
      PRICES / AMOUNTS:

       
      	
              CLIN/ELIN

            	
              Noun

            	
              Qty

            	
              Unit

            	
              Unit Price

            	
              Total Line Item Amount

            
	
              002

            	
              COVID-19 TE

            	
              6000000

            	
              EA

            	
              USD [**]

            	
              USD [**]

            

       
      

         

       
      DESCRIPTION:

       
      	
              CLIN/ELIN

            	
              NSN

            	
              Part

              Number

            	
              Qty Variance

              Over

            	
              Qty Variance

              Under

            	
              Requisition

              Number

            	
              ACRN

            
	
              0002

            	
              N

            	 	 	 	
              0011560601

            	
              AA

            
	 	
              COVID-19 Test Cartridges

            

       
      

         

       
      INSPECTION AND ACCEPTANCE:

       
      	
              CLIN/ELIN

            	
              FOB

            	
              Inspection

            	
              Acceptance

            	
              Serv

              Comp Dt

            	
              Transport

              Priority

            	
              Days for

              Acceptance

            
	
              0002

            	
              D

            	
              S

            	
              S

            	 	 	 

       
      

         

       
      CLOSING REMARKS:

       
      The USD Cost Amount is USD 0.00.

       
      The USD Fee Amount is USD 0.00.

       
      The total funds obligated to this Contract equal USD 480,916,636.62.

       
      The USD Total Contract Amount is USD 480,916,636.62.

       
      

         

       
      As a result of this modification, the total obligated amount of this contract is unchanged. The total contract amount of this contract is unchanged.

       
      Except as provided by this contract modification, all terms and conditions of this contract remain unchanged and in full force and effect.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]